

1. NAME OF THE MEDICINAL PRODUCT

IMFINZI 50 mg/ml concentrate for solution for infusion.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml of concentrate for solution for infusion contains 50 mg of durvalumab.

One vial of 2.4 ml of concentrate contains 120 mg of durvalumab.

One vial of 10 ml of concentrate contains 500 mg of durvalumab.

Durvalumab is produced in mammalian (Chinese hamster ovary) cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Concentrate for solution for infusion (sterile concentrate).

Clear to opalescent, colourless to slightly yellow solution, free from visible particles. The solution has a pH of approximately 6.0 and an osmolality of approximately 400 mOsm/kg.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Non-Small Cell Lung Cancer (NSCLC)

IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy as adjuvant treatment, is indicated for the treatment of adults with resectable NSCLC at high risk of recurrence and no EGFR mutations or ALK rearrangements (for selection criteria, see section 5.1).

IMFINZI as monotherapy is indicated for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on $\geq 1\%$ of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy (see section 5.1).

IMFINZI in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic NSCLC with no sensitising EGFR mutations or ALK positive mutations.

Small Cell Lung Cancer (SCLC)

IMFINZI as monotherapy is indicated for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy.

IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).

Biliary Tract Cancer (BTC)

IMFINZI in combination with gemcitabine and cisplatin is indicated for the first-line treatment of adults with unresectable or metastatic biliary tract cancer (BTC).

Hepatocellular Carcinoma (HCC)

IMFINZI as monotherapy is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).

IMFINZI in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).

Endometrial Cancer

IMFINZI in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with:

- IMFINZI as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR)
- IMFINZI in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).

Muscle Invasive Bladder Cancer (MIBC)

IMFINZI in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as monotherapy adjuvant treatment after radical cystectomy, is indicated for the treatment of adults with resectable muscle invasive bladder cancer (MIBC).

Gastric or Gastro-oesophageal Junction Adenocarcinoma (GC/GEJC)

IMFINZI in combination with FLOT chemotherapy as neoadjuvant and adjuvant treatment, followed by adjuvant IMFINZI monotherapy, is indicated for the treatment of adults with resectable gastric or gastro-oesophageal junction adenocarcinoma.

4.2 Posology and method of administration

Treatment must be initiated and supervised by a physician experienced in the treatment of cancer.

PD-L1 testing for patients with locally advanced NSCLC

Patients with locally advanced NSCLC should be evaluated for treatment based on the tumour expression of PD-L1 confirmed by a validated test (see section 5.1).

MMR testing for patients with endometrial cancer

Patients with endometrial cancer should be evaluated for treatment based on tumour MMR status confirmed by a validated test (see section 5.1).

Posology

The recommended dose for IMFINZI monotherapy and IMFINZI combination therapy is presented in Table 1. IMFINZI is administered as an intravenous infusion over 1 hour.

When IMFINZI is administered in combination with other therapeutic agents, refer to the summary of product characteristics (SmPC) of the therapeutic agents for further information.

Table 1. Recommended dose of IMFINZI monotherapy and combination therapy

Indication	Recommended IMFINZI dose	Duration of therapy
Monotherapy		
Locally Advanced NSCLC	10 mg/kg every 2 weeks or 1 500 mg every 4 weeks ^a	Until disease progression, unacceptable toxicity, or a maximum of 12 months ^b
LS-SCLC	1 500 mg every 4 weeks ^a	Until disease progression, unacceptable toxicity, or a maximum of 24 months
HCC	1 500 mg every 4 weeks ^a	Until disease progression or until unacceptable toxicity

Indication	Recommended IMFINZI dose	Duration of therapy
Combination therapy		
Resectable NSCLC	1 500 mg^c in combination with platinum-based chemotherapy every 3 weeks for up to 4 cycles prior to surgery, followed by 1 500 mg monotherapy every 4 weeks for up to 12 cycles after surgery.	Neoadjuvant phase: until disease progression that precludes definitive surgery or unacceptable toxicity. Adjuvant phase: until recurrence, unacceptable toxicity, or a maximum of 12 cycles after surgery.
Metastatic NSCLC	During platinum chemotherapy: 1 500 mg^d in combination with tremelimumab 75 mg^d and platinum-based chemotherapy every 3 weeks (21 days) for 4 cycles (12 weeks) Post-platinum chemotherapy: 1 500 mg every 4 weeks as monotherapy and histology-based pemetrexed maintenance^e therapy every 4 weeks A fifth dose of tremelimumab 75 mg^{f,g} should be given at week 16 alongside IMFINZI	Until disease progression or unacceptable toxicity
ES-SCLC	1 500 mg^h in combination with chemotherapy every 3 weeks (21 days) for 4 cycles, followed by 1 500 mg every 4 weeks as monotherapy	Until disease progression or unacceptable toxicity
BTC	1 500 mgⁱ in combination with chemotherapy every 3 weeks (21 days) up to 8 cycles, followed by 1 500 mg every 4 weeks as monotherapy	Until disease progression or until unacceptable toxicity
HCC	IMFINZI 1 500 mg^j administered in combination with 300 mg^j tremelimumab as a single dose at Cycle 1/Day 1, followed by IMFINZI as monotherapy every 4 weeks	Until disease progression or unacceptable toxicity
Endometrial Cancer	1 120 mg in combination with carboplatin and paclitaxel every 3 weeks (21 days) for a minimum of 4 and up to 6 cycles, followed by IMFINZI 1 500 mg^k every 4 weeks as monotherapy (dMMR patients) or in combination with olaparib	Until disease progression or unacceptable toxicity

Indication	Recommended IMFINZI dose	Duration of therapy
	300 mg twice daily (pMMR patients)	
MIBC	1 500 mg ^l in combination with chemotherapy every 3 weeks for 4 cycles prior to surgery, followed by 1 500 mg ^l every 4 weeks as monotherapy for up to 8 cycles after surgery	Neoadjuvant phase: until disease progression that precludes definitive surgery or unacceptable toxicity Adjuvant phase: until recurrence, unacceptable toxicity, or a maximum of 8 cycles after surgery
GC/GEJC	1 500 mg ^m in combination with FLOT chemotherapy every 4 weeks for up to 2 cycles prior to surgery, followed by 1 500 mg ^m , with FLOT chemotherapy, every 4 weeks for up to 2 cycles and then as 1 500 mg monotherapy every 4 weeks for up to 10 cycles, for a total of up to 12 cycles after surgery	Neoadjuvant phase: until disease progression that precludes definitive surgery or unacceptable toxicity Adjuvant phase: until progression or recurrence, unacceptable toxicity, or a maximum of 12 cycles after surgery

^a Patients with a body weight of 30 kg or less must receive weight-based dosing, equivalent to IMFINZI

10 mg/kg every 2 weeks or 20 mg/kg every 4 weeks as monotherapy until weight increases to greater than 30 kg.

^b It is recommended to continue treatment for clinically stable patients with initial evidence of disease progression until disease progression is confirmed.

^c Resectable NSCLC patients with a body weight of 30 kg or less must receive weight-based dosing of IMFINZI at 20 mg/kg. In combination with platinum-based chemotherapy dose at 20 mg/kg every 3 weeks (21 days) prior to surgery, followed by monotherapy at 20 mg/kg every 4 weeks after surgery until weight increases to greater than 30 kg.

^d Metastatic NSCLC patients with a body weight of 30 kg or less must receive weight-based dosing, equivalent to IMFINZI 20 mg/kg until weight increases to greater than 30 kg. Patients with a body weight of 34 kg or less must receive weight-based dosing equivalent to tremelimumab 1 mg/kg until weight increases to greater than 34 kg.

^e Consider maintenance administration of pemetrexed for patients with non-squamous tumours who received treatment with pemetrexed and carboplatin/cisplatin during the platinum-based chemotherapy stage.

^f In the case of dose delay(s), a fifth dose of tremelimumab can be given after Week 16, alongside IMFINZI.

^g If patients receive fewer than 4 cycles of platinum-based chemotherapy, the remaining cycles of tremelimumab (up to a total of 5) alongside IMFINZI should be given during the post-platinum chemotherapy phase.

^h ES-SCLC patients with a body weight of 30 kg or less must receive weight-based dosing of IMFINZI at 20 mg/kg. In combination with chemotherapy dose every 3 weeks (21 days), followed by 20 mg/kg every 4 weeks as monotherapy until weight increases to greater than 30 kg.

ⁱ BTC patients with a body weight of 36 kg or less must receive weight-based dosing of IMFINZI at 20 mg/kg. In combination with chemotherapy dose every 3 weeks (21 days), followed by 20 mg/kg every 4 weeks as monotherapy until weight increases to greater than 36 kg.

^j HCC patients with a body weight of 30 kg or less must receive weight-based dosing, equivalent to IMFINZI 20 mg/kg until weight increases to greater than 30 kg. Patients with a body weight of 40 kg or less must receive weight-based dosing, equivalent to tremelimumab 4 mg/kg until weight increases to greater than 40 kg.

^k Endometrial cancer patients with a body weight of 30 kg or less during maintenance phase must receive weight-based dosing equivalent to IMFINZI at 20 mg/kg, until weight increases to greater than 30 kg.

^l MIBC patients with a body weight of 30 kg or less must receive weight-based dosing of IMFINZI at 20 mg/kg.

^m GC/GEJC patients with a body weight of 30 kg or less must receive weight-based dosing of IMFINZI at 20 mg/kg.

Dose escalation or reduction is not recommended. Treatment withholding or discontinuation may be required based on individual safety and tolerability, see Table 2.

Guidelines for management of immune-mediated and non-immune-mediated adverse reactions are described in Table 2 (refer to section 4.4 for further management recommendations, monitoring and evaluation information).

Table 2. Treatment modifications for IMFINZI or IMFINZI in combination with other products

Adverse reactions	Severity ^a	Treatment modification
Immune-mediated adverse reactions		
Immune-mediated pneumonitis/interstitial lung disease	Grade 2	Withhold dose
	Grade 3 or 4	Permanently discontinue
Immune-mediated hepatitis	ALT or AST > 3 - ≤ 5 x ULN or total bilirubin > 1.5 - ≤ 3 x ULN	Withhold dose
	ALT or AST > 5 - ≤ 10 x ULN	Withhold IMFINZI and permanently discontinue tremelimumab (where appropriate)
	Concurrent ALT or AST > 3 x ULN and total bilirubin > 2 x ULN ^b	Permanently discontinue
	ALT or AST > 10 x ULN or total bilirubin > 3 x ULN	
Immune-mediated hepatitis in HCC (or secondary tumour involvement of the liver with abnormal baseline values) ^c	ALT or AST > 2.5 - ≤ 5 x BLV and ≤ 20 x ULN	Withhold dose
	ALT or AST > 5 - 7 x BLV and ≤ 20 x ULN or	Withhold IMFINZI and permanently discontinue tremelimumab (where appropriate).

Adverse reactions	Severity ^a	Treatment modification
	concurrent ALT or AST 2.5 - 5 x BLV and ≤ 20 x ULN and total bilirubin $> 1.5 - < 2$ x ULN ^b	
	ALT or AST > 7 x BLV or > 20 ULN whichever occurs first or bilirubin > 3 X ULN	Permanently discontinue
Immune-mediated colitis or diarrhoea	Grade 2	Withhold dose
	Grade 3 for IMFINZI monotherapy	Withhold dose
	Grade 3 for IMFINZI + tremelimumab	Permanently discontinue tremelimumab ^d
	Grade 4	Permanently discontinue
Intestinal perforation ^c	Any grade	Permanently discontinue
Immune-mediated hyperthyroidism, thyroiditis	Grade 2-4	Withhold dose until clinically stable
Immune-mediated hypothyroidism	Grade 2-4	No changes
Immune-mediated adrenal insufficiency or hypophysitis/hypopituitarism	Grade 2-4	Withhold dose until clinically stable
Immune-mediated type 1 diabetes mellitus	Grade 2-4	No changes
Immune-mediated nephritis	Grade 2 with serum creatinine $> 1.5 - 3$ x (ULN or baseline)	Withhold dose
	Grade 3 with serum creatinine > 3 x baseline or $> 3-6$ x ULN; Grade 4	Permanently discontinue

Adverse reactions	Severity ^a	Treatment modification
	with serum creatinine > 6 x ULN	
Immune-mediated rash or dermatitis (including pemphigoid)	Grade 2 for > 1 week	Withhold dose
	Grade 3	
	Grade 4	Permanently discontinue
Immune-mediated myocarditis	Grade 2-4	Permanently discontinue
Immune-mediated myositis/polymyositis/rhabdomyolysis	Grade 2 or 3	Withhold dose ^f
	Grade 4	Permanently discontinue
Infusion-related reactions	Grade 1 or 2	Interrupt or slow the rate of infusion
	Grade 3 or 4	Permanently discontinue
Infection	Grade 3 or 4	Withhold dose until clinically stable
Immune-mediated myasthenia gravis	Grade 2-4	Permanently discontinue
Immune-mediated Myelitis transverse	Any grade	Permanently discontinue
Immune-mediated meningitis	Grade 2	Withhold dose
	Grade 3 or 4	Permanently discontinue
Immune-mediated encephalitis	Grade 2-4	Permanently discontinue
Immune-mediated Guillain-Barré syndrome	Grade 2-4	Permanently discontinue
Other immune-mediated adverse reactions ^g	Grade 2 or 3	Withhold dose
	Grade 4	Permanently discontinue
Non-immune-mediated adverse reactions		
Pure red cell aplasia (PRCA) ^h	Any Grade	Permanently discontinue

Adverse reactions	Severity ^a	Treatment modification
Other non-immune-mediated adverse reactions	Grade 2 and 3	Withhold dose until $\leq$ Grade 1 or return to baseline
	Grade 4	Permanently discontinue ⁱ

^a Common Terminology Criteria for Adverse Events, version 4.03. ALT: alanine aminotransferase; AST: aspartate aminotransferase; ULN: upper limit of normal; BLV: baseline value.

^b For patients with alternative cause follow the recommendations for AST or ALT increases without concurrent bilirubin elevations.

^c If AST and ALT are less than or equal to ULN at baseline in patients with liver involvement, withhold or permanently discontinue durvalumab based on recommendations for hepatitis with no liver involvement.

^d Permanently discontinue tremelimumab for Grade 3; however, treatment with durvalumab can be resumed once event has resolved.

^e Adverse drug reaction is only associated with IMFINZI in combination with tremelimumab.

^f Permanently discontinue IMFINZI if adverse reaction does not resolve to $\leq$ Grade 1 within 30 days or if there are signs of respiratory insufficiency.

^g Includes immune thrombocytopenia, pancreatitis, immune-mediated arthritis, uveitis, cystitis noninfective and polymyalgia rheumatica.

^h Adverse drug reaction is only associated when olaparib maintenance treatment is used in combination with IMFINZI, following treatment with IMFINZI in combination with platinum-based chemotherapy.

ⁱ With the exception of Grade 4 laboratory abnormalities, about which the decision to discontinue should be based on accompanying clinical signs/symptoms and clinical judgment.

Based on the severity of the adverse reaction, IMFINZI and/or tremelimumab should be withheld and corticosteroids administered (refer to section 4.4). After withhold, IMFINZI and/or tremelimumab can be resumed within 12 weeks if the adverse reactions improved to $\leq$ Grade 1 and the corticosteroid dose has been reduced to $\leq$ 10 mg prednisone or equivalent per day. IMFINZI and tremelimumab should be permanently discontinued for recurrent Grade 3 (severe) immune-mediated adverse reactions and for any Grade 4 (life-threatening) immune-mediated adverse reactions, except for endocrinopathies that are controlled with replacement hormones.

Special populations

Elderly

No dose adjustment is required for elderly patients ($\geq$ 65 years of age) (see section 5.1).

Renal impairment

No dose adjustment of IMFINZI is recommended in patients with mild or moderate renal impairment. Data from patients with severe renal impairment are too limited to draw conclusions on this population (see section 5.2).

Hepatic impairment

No dose adjustment of IMFINZI is recommended for patients with mild or moderate hepatic impairment. Data from patients with severe hepatic impairment are too limited to draw conclusions on this population (see section 5.2).

Paediatric population

The safety and efficacy of IMFINZI in children and adolescents aged below 18 years of age has not been established with regard to NSCLC, SCLC, BTC, HCC, endometrial cancer and GC/GEJC. No data are available. Outside its authorised indications, IMFINZI in combination with tremelimumab has been studied in children aged 1 to 17 years with neuroblastoma, solid tumour and sarcoma, however the results of the study did not allow to conclude that the benefits of such use outweigh the risks. Currently available data are described in sections 5.1 and 5.2.

Method of administration

IMFINZI is for intravenous use. It is to be administered as an intravenous infusion solution over 1 hour (see section 6.6).

For instructions on dilution of the medicinal product before administration, see section 6.6.

IMFINZI in combination with chemotherapy

When IMFINZI is administered in combination with chemotherapy, administer IMFINZI prior to chemotherapy on the same day.

IMFINZI in combination with tremelimumab and platinum-based chemotherapy

When IMFINZI is administered in combination with tremelimumab and platinum-based chemotherapy, tremelimumab is given first, followed by IMFINZI and then platinum-based chemotherapy on the same day of dosing.

When IMFINZI is administered in combination with a fifth dose of tremelimumab and pemetrexed maintenance therapy at week 16, tremelimumab is given first, followed by IMFINZI and then pemetrexed maintenance therapy on the same day of dosing.

IMFINZI, tremelimumab, and platinum-based chemotherapy are administered as separate intravenous infusions. IMFINZI and tremelimumab are each given over 1 hour. For platinum-based chemotherapy, refer to the SmPC for administration information. For pemetrexed maintenance therapy, refer to the SmPC for administration information. Separate infusion bags and filters for each infusion should be used.

During cycle 1, tremelimumab is to be followed by IMFINZI starting approximately 1 hour (maximum 2 hours) after the end of the tremelimumab infusion. Platinum-based chemotherapy infusion should start approximately 1 hour (maximum 2 hours) after the end of the IMFINZI infusion. If there are no clinically significant concerns during cycle 1, then at the physician's discretion, subsequent cycles of IMFINZI can be given immediately after tremelimumab and the time period between the end of the IMFINZI infusion and the start of chemotherapy can be reduced to 30 minutes.

IMFINZI in combination with tremelimumab

When IMFINZI is administered in combination with tremelimumab, administer tremelimumab prior to IMFINZI on the same day. IMFINZI and tremelimumab are administered as separate intravenous infusions. Refer to the SmPC for tremelimumab dosing information.

4.3 Contraindications

Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Refer to section 4.2, Table 2 for recommended treatment modifications.

For suspected immune-mediated adverse reactions, adequate evaluation should be performed to confirm etiology or exclude alternate etiologies. Based on the severity of the adverse reaction, IMFINZI or IMFINZI in combination with tremelimumab should be withheld or permanently discontinued. Treatment with corticosteroids or endocrine therapy should be initiated. For events requiring corticosteroid therapy, and upon improvement to $\leq$ Grade 1, corticosteroid taper should be initiated and continued over at least 1 month. Consider increasing dose of corticosteroids and/or using additional systemic immunosuppressants if there is worsening or no improvement.

Traceability

In order to improve the traceability of biological medicinal products, the tradename and the batch number of the administered product should be clearly recorded.

Immune-mediated pneumonitis

Immune-mediated pneumonitis or interstitial lung disease, defined as requiring use of systemic corticosteroids and with no clear alternate aetiology, occurred in patients receiving IMFINZI, IMFINZI in combination with tremelimumab, IMFINZI in combination with platinum-based chemotherapy followed by IMFINZI in combination with olaparib, or in combination with chemotherapy (see section 4.8). For Grade 2 events, an initial dose of 1-2 mg/kg/day prednisone or equivalent should be initiated followed by a taper. For Grade 3 or 4 events, an initial dose of 2-4 mg/kg/day methylprednisolone or equivalent should be initiated followed by a taper.

Pneumonitis and radiation pneumonitis

Radiation pneumonitis is frequently observed in patients receiving radiation therapy to the lung and the clinical presentation of pneumonitis and radiation pneumonitis is very similar. In the PACIFIC Study, in patients who had completed treatment with at least 2 cycles of concurrent chemoradiation within 1 to 42 days prior to initiation of study treatment, pneumonitis or radiation pneumonitis occurred in 161 (33.9%) patients in the IMFINZI-treated group and 58 (24.8%) in the placebo group, including Grade 3 (3.4% vs. 3.0%) and Grade 5 (1.1% vs. 1.7%). In the AEGEAN study, in patients who have received post-operative radiotherapy (PORT), pneumonitis and radiation pneumonitis occurred in 10 (33.3%) patients in the IMFINZI-treated group and 3 (11.1%) patients in the placebo group, including 2 patients with maximum Grade 3 (6.7%) in the IMFINZI-treated group.

In the ADRIATIC Study, in patients who had completed chemoradiation within 1 to 42 days prior to initiation of study treatment, pneumonitis or radiation pneumonitis occurred in 100 (38.2%) patients in the IMFINZI-treated group and 80 (30.2%) in the placebo group, including Grade 3 (3.1% vs. 2.3%), and Grade 5 (0.4% vs. 0.0%).

Patients should be monitored for signs and symptoms of pneumonitis or radiation pneumonitis. Suspected pneumonitis should be confirmed with radiographic imaging and other infectious and disease-related aetiologies excluded, and managed as recommended in section 4.2.

Immune-mediated hepatitis

Immune-mediated hepatitis, defined as requiring use of systemic corticosteroids and with no clear alternate aetiology, occurred in patients receiving IMFINZI or IMFINZI in combination with tremelimumab, or in combination with chemotherapy (see section 4.8). Monitor alanine aminotransferase, aspartate aminotransferase, total bilirubin, and alkaline phosphatase levels prior to initiation of treatment and prior to each subsequent infusion. Additional monitoring is to be considered based on clinical evaluation. Immune-mediated hepatitis should be managed as recommended in section 4.2. Corticosteroids should be administered with an initial dose of 1-2 mg/kg/day prednisone or equivalent followed by taper for all grades.

Immune-mediated colitis

Immune-mediated colitis or diarrhoea, defined as requiring use of systemic corticosteroids and with no clear alternate aetiology, occurred in patients receiving IMFINZI or IMFINZI in combination with tremelimumab, or in combination with chemotherapy (see section 4.8). Adverse drug reactions of intestinal perforation and large intestine perforation were reported in patients receiving IMFINZI in combination with tremelimumab. Patients should be monitored for signs and symptoms of colitis/diarrhoea and intestinal perforation and managed as recommended in section 4.2. Corticosteroids should be administered at an initial dose of 1-2 mg/kg/day prednisone or equivalent followed by a taper for Grades 2-4. Consult a surgeon immediately if intestinal perforation of ANY grade is suspected.

Immune-mediated endocrinopathies

Immune-mediated hypothyroidism, hyperthyroidism and thyroiditis

Immune-mediated hypothyroidism, hyperthyroidism and thyroiditis occurred in patients receiving IMFINZI or IMFINZI in combination with tremelimumab, or in combination with chemotherapy and hypothyroidism may follow hyperthyroidism (see section 4.8). Patients should be monitored for abnormal thyroid function tests prior to and periodically during treatment and as indicated based on clinical evaluation. Immune-mediated hypothyroidism, hyperthyroidism, and thyroiditis should be managed as recommended in section 4.2. For immune-mediated hypothyroidism, initiate thyroid hormone replacement as clinically indicated for Grades 2-4. For immune-mediated hyperthyroidism/thyroiditis, symptomatic management can be implemented for Grades 2-4.

Immune-mediated adrenal insufficiency

Immune-mediated adrenal insufficiency occurred in patients receiving IMFINZI or IMFINZI in combination with tremelimumab, or in combination with chemotherapy (see section 4.8). Patients should be monitored for clinical signs and symptoms of adrenal insufficiency. For symptomatic adrenal insufficiency, patients should be managed as recommended in section 4.2. Corticosteroids should be administered with an initial dose of 1-2 mg/kg/day prednisone or equivalent followed by a taper and a hormone replacement as clinically indicated for Grades 2-4.

Immune-mediated type 1 diabetes mellitus

Immune-mediated type 1 diabetes mellitus, which can first present as diabetic ketoacidosis that can be fatal if not detected early, occurred in patients receiving IMFINZI or IMFINZI in combination with tremelimumab, or in combination with chemotherapy (see section 4.8). Patients should be monitored for clinical signs and symptoms of type 1 diabetes mellitus. For symptomatic type 1 diabetes mellitus, patients should be managed as recommended in section 4.2. Treatment with insulin can be initiated as clinically indicated for Grades 2-4.

Immune-mediated hypophysitis/hypopituitarism

Immune-mediated hypophysitis or hypopituitarism occurred in patients receiving IMFINZI or IMFINZI in combination with tremelimumab, or in combination with chemotherapy (see section 4.8). Patients should be monitored for clinical signs and symptoms of hypophysitis or hypopituitarism. For symptomatic hypophysitis or hypopituitarism, patients should be managed as recommended in section 4.2. Corticosteroids should be administered with an initial dose of 1-2 mg/kg/day prednisone or equivalent followed by a taper and a hormone replacement as clinically indicated for Grades 2-4.

Immune-mediated nephritis

Immune-mediated nephritis, defined as requiring use of systemic corticosteroids and with no clear alternate aetiology, occurred in patients receiving IMFINZI or IMFINZI in combination with tremelimumab, or in combination with chemotherapy (see section 4.8). Patients should be monitored for abnormal renal function tests prior to and periodically during treatment with IMFINZI or IMFINZI in combination with tremelimumab and managed as recommended in section 4.2. Corticosteroids should be administered with an initial dose of 1-2 mg/kg/day prednisone or equivalent followed by a taper for Grades 2-4.

Immune-mediated rash

Immune-mediated rash or dermatitis (including pemphigoid), defined as requiring use of systemic corticosteroids and with no clear alternate aetiology, occurred in patients receiving IMFINZI or IMFINZI in combination with tremelimumab, or in combination with chemotherapy (see section 4.8). Events of Stevens-Johnson Syndrome or toxic epidermal necrolysis have been reported in patients treated with PD-1 inhibitors. Patients should be monitored for signs and symptoms of rash or dermatitis and managed as recommended in section 4.2. Corticosteroids should be administered with an initial dose of 1-2 mg/kg/day prednisone or equivalent followed by a taper for Grade 2 > 1 week or Grade 3 and 4.

Immune-mediated myocarditis

Immune-mediated myocarditis, which can be fatal, occurred in patients receiving IMFINZI or IMFINZI in combination with tremelimumab, or in combination with chemotherapy (see section 4.8). Patients should be monitored for signs and symptoms of immune-mediated myocarditis and managed

as recommended in section 4.2. Corticosteroids should be administered with an initial dose of 2-4 mg/kg/day prednisone or equivalent followed by taper for Grades 2-4. If no improvement within 2 to 3 days despite corticosteroids, promptly start additional immunosuppressive therapy. Upon resolution (Grade 0), corticosteroid taper should be initiated and continued over at least 1 month.

Immune-mediated pancreatitis

Immune-mediated pancreatitis occurred in patients receiving IMFINZI in combination with tremelimumab and chemotherapy, or in combination with chemotherapy (see section 4.8). Patients should be monitored for signs and symptoms of immune-mediated pancreatitis and managed as recommended in section 4.2.

Other immune-mediated adverse reactions

Given the mechanism of action of IMFINZI or IMFINZI in combination with tremelimumab, other potential immune-mediated adverse reactions may occur. The following immune-related adverse reactions have been observed in patients treated with IMFINZI monotherapy or IMFINZI in combination with tremelimumab, or in combination with chemotherapy: myasthenia gravis, myelitis transverse, myositis, polymyositis, rhabdomyolysis, meningitis, encephalitis, Guillain-Barré syndrome, immune thrombocytopenia, immune-mediated arthritis, uveitis, cystitis noninfective and polymyalgia rheumatica (see section 4.8). Patients should be monitored for signs and symptoms and managed as recommended in section 4.2. Corticosteroids should be administered with an initial dose of 1-2 mg/kg/day prednisone or equivalent followed by taper for Grades 2-4.

Infusion-related reactions

Patients should be monitored for signs and symptoms of infusion-related reactions. Severe infusion-related reactions have been reported in patients receiving IMFINZI or IMFINZI in combination with tremelimumab, or in combination with chemotherapy (see section 4.8). Infusion-related reactions should be managed as recommended in section 4.2. For Grade 1 or 2 severity, may consider pre-medications for prophylaxis of subsequent infusion reactions. For Grade 3 or 4, manage severe infusion-related reactions per institutional standard, appropriate clinical practice guidelines and/or society guidelines.

Patients with pre-existing autoimmune disease

In patients with pre-existing autoimmune disease (AID), data from observational studies suggest an increased risk of immune-related adverse reactions following immune-checkpoint inhibitor therapy as compared with patients without pre-existing AID. In addition, flares of the underlying AID were frequent, but the majority were mild and manageable.

Disease-specific precaution (BTC)

Cholangitis and biliary tract infections

Cholangitis and biliary tract infections are not uncommon in patients with advanced BTC. Cholangitis events were reported in TOPAZ-1 in both treatment groups (14.5% [IMFINZI + chemotherapy] vs. 8.2% [placebo + chemotherapy]); these were mostly in association with biliary stents and were not immune-mediated in aetiology. Patients with BTC (especially those with biliary stents) should be closely monitored for development of cholangitis or biliary tract infections before initiation of treatment and, regularly, thereafter.

Treatment-specific precaution (IMFINZI in combination with olaparib in endometrial cancer)

Haematological toxicity

Pure red cell aplasia (PRCA) (see section 4.8) was reported when olaparib maintenance treatment was used in combination with IMFINZI, following treatment with IMFINZI in combination with platinum-based chemotherapy. If PRCA is confirmed, treatment with IMFINZI and olaparib should be discontinued.

Autoimmune haemolytic anemia (AIHA) was reported when olaparib maintenance treatment was used in combination with IMFINZI, following treatment with IMFINZI in combination with platinum-based chemotherapy. If AIHA is confirmed, treatment with IMFINZI and olaparib should be discontinued.

Metastatic NSCLC

Limited data are available in elderly patients (≥ 75 years) treated with IMFINZI in combination with tremelimumab and platinum-based chemotherapy (see sections 4.8 and 5.1). Careful consideration of the potential benefit/risk of this regimen on an individual basis is recommended.

Patients excluded from clinical studies

Patients with the following were excluded from clinical studies: a baseline ECOG performance score ≥ 2 ; active or prior documented autoimmune disease within 2 years of initiation of the study; a history of immunodeficiency; a history of severe immune-mediated adverse reactions; medical conditions that required systemic immunosuppression, except physiological dose of systemic corticosteroids (≤ 10 mg/day prednisone or equivalent); uncontrolled intercurrent illnesses; active tuberculosis or hepatitis B or C or HIV infection or patients receiving live attenuated vaccine within 30 days before or after the start of IMFINZI. In the absence of data, durvalumab should be used with caution in these populations after careful consideration of the potential benefit/risk on an individual basis. The safety of concurrent prophylactic cranial irradiation (PCI) with IMFINZI in patients with ES-SCLC is unknown.

For more information on exclusion criteria for each specific study see section 5.1.

4.5 Interaction with other medicinal products and other forms of interaction

The use of systemic corticosteroids or immunosuppressants before starting durvalumab, except physiological dose of systemic corticosteroids (≤ 10 mg/day prednisone or equivalent), is not recommended because of their potential interference with the pharmacodynamic activity and efficacy of durvalumab. However, systemic corticosteroids or other immunosuppressants can be used after starting durvalumab to treat immune-related adverse reactions (see section 4.4).

No formal pharmacokinetic (PK) drug-drug interaction studies have been conducted with durvalumab. Since the primary elimination pathways of durvalumab are protein catabolism via reticuloendothelial system or target-mediated disposition, no metabolic drug-drug interactions are expected. PK drug-drug interactions of durvalumab in combination with other therapeutic agents were compared with durvalumab in the CASPIAN, POSEIDON, HIMALAYA, and DUO-E studies; no clinically meaningful PK drug-drug interactions were identified.

4.6 Fertility, pregnancy and lactation

Women of childbearing potential/Contraception

Women of childbearing potential should use effective contraception during treatment with durvalumab and for at least 3 months after the last dose of durvalumab.

Pregnancy

There are no data on the use of durvalumab in pregnant women. Based on its mechanism of action, durvalumab has the potential to impact maintenance of pregnancy, and in a mouse allogeneic pregnancy model, disruption of PD-L1 signaling was shown to result in an increase in foetal loss. Animal studies with durvalumab are not indicative of reproductive toxicity (see section 5.3). Human IgG1 is known to cross the placental barrier and placental transfer of durvalumab was confirmed in animal studies. Durvalumab may cause foetal harm when administered to a pregnant woman and is not recommended during pregnancy and in women of childbearing potential not using effective contraception during treatment and for at least 3 months after the last dose.

Breast-feeding

It is unknown whether durvalumab is secreted in human breast milk. Available toxicological data in cynomolgus monkeys have shown low levels of durvalumab in breast milk on day 28 after birth (see section 5.3). In humans, antibodies may be transferred to breast milk, but the potential for absorption and harm to the newborn is unknown. However, a potential risk to the breast-fed child cannot be

excluded. A decision must be made whether to discontinue breast-feeding or to discontinue or abstain from durvalumab therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

Fertility

There are no data on the potential effects of durvalumab on fertility in humans or animals.

4.7 Effects on ability to drive and use machines

Durvalumab has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

Summary of the safety profile

IMFINZI as monotherapy

The safety of IMFINZI as monotherapy is based on pooled data in 4 642 patients across multiple tumour types. IMFINZI was administered at a dose of 10 mg/kg every 2 weeks, 20 mg/kg every 4 weeks or 1 500 mg every 4 weeks. The most common (> 10%) adverse reactions were cough/productive cough (18.1%), diarrhoea (15.1%), rash (15.0%), arthralgia (12.4%), pyrexia (12.5%), abdominal pain (11.8%), upper respiratory tract infections (11.8%), pruritus (11.1%), and hypothyroidism (11.6%). The most common (> 2%) NCI CTCAE Grade $\geq$ 3 adverse reactions were pneumonia (3.4%) and aspartate aminotransferase increased/alanine aminotransferase increased (2.5%).

IMFINZI was discontinued due to adverse reactions in 3.9% of patients. The most common adverse reactions leading to treatment discontinuation were pneumonitis (1.1%) and pneumonia (0.8%).

IMFINZI was delayed or interrupted due to adverse reactions in 13.1% of patients. The most common adverse reactions leading to dose delay or interruption were pneumonia (2.3%) and aspartate aminotransferase increased/alanine aminotransferase increased (2.0%).

The safety of IMFINZI as monotherapy in patients treated for HCC is based on data in 492 patients and was consistent with the overall safety profile in the IMFINZI monotherapy pool (N=4 642). The most common (> 10%) adverse reactions were AST increased/ALT increased (20.3%), abdominal pain (17.9%), diarrhoea (15.9%), pruritus (15.4%), and rash (15.2%). The most common (> 2%) Grade $\geq$ 3 adverse reactions were AST increased/ALT increased (8.1%) and abdominal pain (2.2%).

IMFINZI was discontinued due to adverse reactions in 3.7% of patients. The most common adverse reactions leading to treatment discontinuation were AST increased/ALT increased (0.8%) and hepatitis (0.6%).

IMFINZI was delayed or interrupted due to adverse reactions in 11.6% of patients. The most common adverse reaction leading to dose delay or interruption was AST increased/ALT increased (5.9%).

IMFINZI in combination with chemotherapy

The safety of IMFINZI in combination with chemotherapy is based on pooled data in 2 244 patients from 6 studies (TOPAZ-1, CASPIAN, DUO-E, AEGEAN, NIAGARA and MATTERHORN). The most common (> 10%) adverse reactions were neutropenia (44.6%), nausea (42.4%), fatigue (41.2%), anaemia (37.4%), diarrhoea (27.5%), constipation (26.7%), decreased appetite (24.0%), alopecia (22.0%), neuropathy peripheral (21.6%), thrombocytopenia (19.7%), rash (19.7%), vomiting (18.8%), abdominal pain (17.9%), pyrexia (15.2%), leukopenia (14.9%), pruritus (12.5%), hypothyroidism (11.1%), arthralgia (10.9%), cough/productive cough (10.8%), and aspartate aminotransferase increased/alanine aminotransferase increased (10.5%). The most common (> 2%) NCI CTCAE Grade $\geq$ 3 adverse reactions were neutropenia (28.5%), anaemia (11.9%), thrombocytopenia (5.6%), leukopenia (4.9%), fatigue (3.3%), pneumonia (2.5%), febrile neutropenia (2.4%), and diarrhoea (2.3%).

IMFINZI was discontinued due to adverse reactions in 6.2% of patients. The most common adverse reactions leading to treatment discontinuation were pneumonitis (0.8%), rash (0.6%), hepatitis (0.5%), and fatigue (0.5%).

IMFINZI was delayed or interrupted due to adverse reactions in 32.4% of patients. The most common adverse reactions leading to dose delay or interruption were neutropenia (15.5%), thrombocytopenia (4.1%), anaemia (3.3%), leukopenia (2.0%), fatigue (2.0%), and aspartate aminotransferase increased/alanine aminotransferase increased (2.0%).

IMFINZI in combination with tremelimumab 75 mg and platinum-based chemotherapy

The safety of IMFINZI given in combination with tremelimumab 75 mg and chemotherapy is based on data in 330 patients with metastatic NSCLC. The most common (> 20%) adverse reactions were anaemia (49.7%), nausea (41.5%), neutropenia (41.2%), fatigue (36.1%), rash (25.8%), thrombocytopenia (24.5%) and diarrhoea (21.5%). The most common (> 2%) NCI CTCAE Grade $\geq$ 3 adverse reactions were neutropenia (23.9%), anaemia (20.6%), pneumonia (9.4%), thrombocytopenia (8.2%), leukopenia (5.5%), fatigue (5.2%), lipase increased (3.9%), amylase increased (3.6%), febrile neutropenia (2.4%), colitis (2.1%) and aspartate aminotransferase increased/alanine aminotransferase increased (2.1%).

IMFINZI was discontinued due to adverse reactions in 8.5% of patients. The most common adverse reactions leading to treatment discontinuation were pneumonia (2.1%) and colitis (1.2%).

IMFINZI was interrupted due to adverse reactions in 49.4% of patients. The most common adverse reactions leading to dose interruption were neutropenia (16.1%), anaemia (10.3%), thrombocytopenia (7.3%), leukopenia (5.8%), pneumonia (5.2%), aspartate aminotransferase increased/alanine aminotransferase increased (4.8%), colitis (3.3%) and pneumonitis (3.3%).

IMFINZI in combination with tremelimumab 300 mg

The safety of IMFINZI given in combination with a single dose of tremelimumab 300 mg is based on pooled data (HCC pool) in 462 HCC patients from the HIMALAYA Study and another study in HCC patients, Study 22. The most common (> 10%) adverse reactions were rash (32.5%), pruritus (25.5%), diarrhoea (25.3%), abdominal pain (19.7%), aspartate aminotransferase increased/alanine aminotransferase increased (18.0%), pyrexia (13.9%), hypothyroidism (13.0%), cough/productive cough (10.8%), oedema peripheral (10.4%) and lipase increased (10.0%) (see Table 4). The most common severe adverse reactions (NCI CTCAE Grade $\geq$ 3) were aspartate aminotransferase increased/alanine aminotransferase increased (8.9%), lipase increased (7.1%), amylase increased (4.3%) and diarrhoea (3.9%).

The most common serious adverse reactions were colitis (2.6%), diarrhoea (2.4%), pneumonia (2.2%), and hepatitis (1.7%).

The frequency of treatment discontinuation due to adverse reactions was 6.5%. The most common adverse reactions leading to treatment discontinuation were hepatitis (1.5%) and aspartate aminotransferase increased/alanine aminotransferase increased (1.3%).

The severity of adverse drug reactions was assessed based on the CTCAE, defining grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life threatening and grade 5=death.

IMFINZI in combination with platinum-based chemotherapy followed by IMFINZI in combination with olaparib 300 mg twice daily

The safety of IMFINZI given in combination with platinum-based chemotherapy followed by IMFINZI in combination with olaparib 300 mg twice daily is based on data in 238 patients with endometrial cancer. The most common (> 20%) adverse reactions were anaemia (61.8%), nausea (54.6%), fatigue (54.2%), neuropathy peripheral (51.7%), alopecia (50.8%), neutropenia (39.5%),

constipation (32.8%), thrombocytopenia (29.8%), diarrhoea (28.2%), vomiting (25.6%), arthralgia (24.4%), rash (23.5%), abdominal pain (23.5%), decreased appetite (23.1%) and leukopenia (20.2%).

The most common (> 2%) NCI CTCAE Grade ≥ 3 adverse reactions were neutropenia (25.2%), anaemia (23.5%), leukopenia (6.7%), thrombocytopenia (5.9%), fatigue (5.5%), febrile neutropenia (3.4%), nausea (2.9%), aspartate aminotransferase increased / alanine aminotransferase increased (2.9%) and neuropathy peripheral (2.5%).

IMFINZI was discontinued in 4.6% of patients. The most common adverse reaction leading to treatment discontinuation was pneumonitis (1.7%).

IMFINZI was interrupted in 38.2% of patients. The most common adverse reactions leading to dose interruption were anaemia (13.4%), thrombocytopenia (11.8%), neutropenia (10.1%), leukopenia (2.9%), hypothyroidism (2.1%) and upper respiratory tract infection (2.1%).

Tabulated list of adverse reactions

Table 3 lists the incidence of adverse reactions in the IMFINZI monotherapy pooled safety dataset (N=4 642), in patients treated with IMFINZI in combination with chemotherapy (N=2 244) and in patients treated with IMFINZI in combination with platinum-based chemotherapy followed by IMFINZI in combination with olaparib (platinum-based chemotherapy + IMFINZI + olaparib) (N=238). Unless otherwise stated, Table 4 lists the incidence of adverse reactions in patients treated with IMFINZI in combination with tremelimumab 75 mg and platinum-based chemotherapy in the POSEIDON study (N=330) and in patients treated with IMFINZI in combination with a single dose of tremelimumab 300 mg in the HCC pool (N=462). Adverse reactions are listed according to system organ class in MedDRA. Within each system organ class, the adverse reactions are presented in decreasing frequency. The corresponding frequency category for each ADR is defined as: very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1\ 000$ to $< 1/100$); rare ($\geq 1/10\ 000$ to $< 1/1\ 000$); very rare ($< 1/10\ 000$); not known (cannot be estimated from available data). Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness.

Table 3. Adverse drug reactions in patients treated with IMFINZI

	IMFINZI as monotherapy	IMFINZI in combination with chemotherapy	Platinum-based chemotherapy + IMFINZI + olaparib*
Infections and infestations			
Very common	Upper respiratory tract infections ^a		Upper respiratory tract infection ^a
Common	Pneumonia ^{b,c} , Influenza, Oral candidiasis, Dental and oral soft tissue infections ^d	Pneumonia ^{b,c} , Upper respiratory tract infections ^a , Dental and oral soft tissue infections ^d	Pneumonia, Oral candidiasis, Dental and oral soft tissue infections ^d
Uncommon		Oral candidiasis, Influenza	Influenza
Blood and lymphatic system disorders			
Very Common		Anaemia, Leukopenia ^e , Neutropenia ^f , Thrombocytopenia ^g	Anaemia ^h , Leukopenia ^h , Neutropenia ^h , Thrombocytopenia ^h
Common		Febrile neutropenia	Aplasia pure red cell, Febrile neutropenia ^h , Lymphopenia ⁱ
Uncommon	Immune thrombocytopenia ^c	Pancytopenia ^c	Pancytopenia ^h
Rare		Immune thrombocytopenia	
Immune system disorders			
Common			Hypersensitivity ^{i,j}
Endocrine disorders			

	IMFINZI as monotherapy	IMFINZI in combination with chemotherapy	Platinum-based chemotherapy + IMFINZI + olaparib*
Very common	Hypothyroidism ^k	Hypothyroidism ^k	Hypothyroidism
Common	Hyperthyroidism ^l	Hyperthyroidism ^l	Hyperthyroidism, Thyroiditis
Uncommon	Thyroiditis ^m , Adrenal insufficiency, Hypophysitis/Hypopituitarism, Type 1 diabetes mellitus	Adrenal insufficiency, Type 1 diabetes mellitus, Hypophysitis/Hypopituitarism, Thyroiditis ^m	
Rare	Diabetes insipidus		
Eye disorders			
Uncommon			Uveitis
Rare	Uveitis	Uveitis	
Metabolism and nutrition disorders			
Very common		Decreased appetite	Decreased appetite ⁿ
Nervous System Disorders			
Very common		Neuropathy peripheral ⁿ	Neuropathy peripheral, Dizziness ⁱ , Headache ⁱ , Dysgeusia ^{i,o}
Uncommon	Myasthenia gravis, Encephalitis ^{c,p}	Myasthenia gravis	
Rare	Meningitis	Encephalitis ^p , Guillain-Barré syndrome	
Not known	Guillain-Barré syndrome, Myelitis transverse ^q		
Vascular disorders			
Common			Venous thromboembolic events ^{i,r}
Rare		Deep vein thrombosis ^s	
Cardiac disorders			
Uncommon	Myocarditis	Acute myocardial infarction ^{t,u} , Myocarditis ^c	
Respiratory, thoracic and mediastinal disorders			
Very common	Cough/Productive Cough	Cough/Productive Cough	Cough/Productive cough, Dyspnoea ^{i,v}
Common	Pneumonitis ^{c,w} , Dysphonia	Pneumonitis ^{c,w} , Dysphonia	Pneumonitis, Dysphonia
Uncommon	Interstitial lung disease	Interstitial lung disease ^c , Pulmonary embolism ^s	Interstitial lung disease
Gastrointestinal disorders			
Very common	Diarrhoea, Abdominal pain ^x	Diarrhoea, Abdominal pain ^x , Constipation, Nausea, Vomiting	Diarrhoea, Abdominal pain ^x , Constipation ^h , Nausea ^h , Vomiting ^h , Stomatitis ^h
Common		Stomatitis ^y , Colitis ^z	Dyspepsia ⁱ , Colitis ^z
Uncommon	Colitis ^{c,z} , Pancreatitis ^{aa}	Pancreatitis ^{aa} , Pancreatic exocrine insufficiency	
Rare	Coeliac disease ^q , Pancreatic exocrine insufficiency	Coeliac disease ^q	
Hepatobiliary disorders			
Very common		Aspartate aminotransferase increased or Alanine aminotransferase increased ^{1bb}	Aspartate aminotransferase increased or Alanine aminotransferase increased

	IMFINZI as monotherapy	IMFINZI in combination with chemotherapy	Platinum-based chemotherapy + IMFINZI + olaparib*
Common	Hepatitis ^{c,cc} , Aspartate aminotransferase increased or Alanine aminotransferase increased ^{c,bb}	Hepatitis ^{c,cc}	
Uncommon			Hepatitis ^{cc}
Skin and subcutaneous tissue disorders			
Very common	Rash ^{dd} , Pruritus	Rash ^{dd} , Alopecia, Pruritus	Rash ^{dd} , Alopecia ^h , Pruritus
Common	Night sweats	Dermatitis	Dermatitis ^{ee}
Uncommon	Dermatitis, Psoriasis, Pemphigoid ^{ff}	Pemphigoid ^{ff} , Night sweats, Psoriasis	Night sweats
Musculoskeletal and connective tissue disorders			
Very common	Arthralgia	Arthralgia	Arthralgia ^h , Myalgia
Common	Myalgia	Myalgia	
Uncommon	Myositis ^{gg} , Immune-mediated arthritis ^{hh}	Immune-mediated arthritis ^{hh} , Myositis ^{gg}	Myositis
Rare	Polymyositis ⁱⁱ , Polymyalgia rheumatica	Polymyalgia rheumatica ^{jj}	Polymyalgia rheumatica ^{jj}
Renal and urinary disorders			
Very common			Blood creatinine increased
Common	Blood creatinine increased, Dysuria	Blood creatinine increased, Dysuria	Dysuria
Uncommon	Nephritis ^{kk} , Cystitis noninfective	Cystitis noninfective, Nephritis ^{kk}	Cystitis noninfective ^h
General disorders and administration site conditions			
Very common	Pyrexia	Pyrexia, Fatigue ^{ll}	Pyrexia, Fatigue ^h , Peripheral oedema ^{mm}
Common	Peripheral oedema ^{mm}	Peripheral oedema ^{mm}	
Injury, poisoning and procedural complications			
Common	Infusion-related reaction ⁿⁿ	Infusion-related reaction ⁿⁿ	Infusion-related reaction

Adverse reaction frequencies may not be fully attributed to durvalumab alone but may contain contributions from the underlying disease or from other medicinal products used in a combination.

* overall study of treatment with up to six 21-day cycles with platinum-based chemotherapy in combination with IMFINZI, followed by IMFINZI in combination with olaparib.

^a includes laryngitis, nasopharyngitis, peritonsillar abscess, pharyngitis, rhinitis, sinusitis, tonsillitis, tracheobronchitis and upper respiratory tract infection.

^b includes pneumocystis jirovecii pneumonia, pneumonia, pneumonia adenoviral, pneumonia bacterial, pneumonia cytomegaloviral, pneumonia haemophilus, pneumonia pneumococcal, pneumonia streptococcal, candida pneumonia, pneumonia klebsiella, and pneumonia legionella.

^c including fatal outcome.

^d includes gingivitis, oral infection, periodontitis, pulpitis dental, tooth abscess and tooth infection.

^e includes leukopenia and white blood cell count decreased.

^f includes neutropenia and neutrophil count decreased.

^g includes thrombocytopenia and platelet count decreased.

^h adverse reaction only applies to chemotherapy ADRs in the DUO-E study.

ⁱ adverse reaction only applies to olaparib ADRs in the DUO-E study.

^j includes drug hypersensitivity and hypersensitivity.

^k includes autoimmune hypothyroidism, hypothyroidism, immune-mediated hypothyroidism, blood thyroid stimulating hormone increased.

^l includes hyperthyroidism, Grave's disease, immune-mediated hyperthyroidism and blood thyroid stimulating hormone decreased.

^m includes autoimmune thyroiditis, immune-mediated thyroiditis, thyroiditis, and thyroiditis subacute.

ⁿ includes neuropathy peripheral, paraesthesia and peripheral sensory neuropathy.

- ^o includes dysgeusia and taste disorder.
- ^p includes encephalitis, encephalitis autoimmune, immune-mediated encephalitis and noninfective encephalitis.
- ^q events were reported from post-marketing data.
- ^r includes deep vein thrombosis, embolism, embolism venous, pelvic venous thrombosis, superficial vein thrombosis and thrombosis.
- ^s adverse reaction only applies to oxaliplatin ADRs in the MATTERHORN study.
- ^t adverse reaction only applies to 5-FU ADRs in the MATTERHORN study.
- ^u includes acute coronary syndrome, acute myocardial infarction, myocardial infarction, myocardial ischaemia, and coronary artery disease.
- ^v includes dyspnoea and dyspnoea exertional.
- ^w includes pneumonitis and immune-mediated lung disease.
- ^x includes abdominal pain, abdominal pain lower, abdominal pain upper and flank pain.
- ^y includes stomatitis and mucosal inflammation.
- ^z includes colitis, enteritis, enterocolitis, immune-mediated enterocolitis and proctitis.
- ^{aa} includes pancreatitis, pancreatitis acute, pancreatitis necrotising and immune-mediated pancreatitis.
- ^{bb} includes alanine aminotransferase increased, aspartate aminotransferase increased, hepatic enzyme increased and transaminases increased.
- ^{cc} includes hepatitis, autoimmune hepatitis, hepatitis toxic, hepatitis acute, hepatotoxicity, immune-mediated hepatitis, and hepatic cytolysis.
- ^{dd} includes rash erythematous, rash macular, rash maculopapular, rash papular, rash pruritic, rash pustular, erythema, eczema and rash.
- ^{ee} includes dermatitis and immune-mediated dermatitis.
- ^{ff} includes pemphigoid, dermatitis bullous and pemphigus. Reported frequency from completed and ongoing studies is uncommon.
- ^{gg} includes myositis and rhabdomyolysis.
- ^{hh} includes autoimmune arthritis, immune-mediated arthritis, polyarthritis, and rheumatoid arthritis.
- ⁱⁱ polymyositis (fatal) was observed in a patient treated with IMFINZI from an ongoing sponsored clinical study outside of the pooled dataset.
- ^{jj} not observed in the IMFINZI+Chemotherapy pool or the platinum-based chemotherapy+IMFINZI+olaparib dataset, but observed in other AstraZeneca-sponsored clinical studies.
- ^{kk} includes autoimmune nephritis, tubulointerstitial nephritis, nephritis, glomerulonephritis, glomerulonephritis membranous, and immune-mediated nephritis.
- ^{ll} includes fatigue and asthenia.
- ^{mm} includes oedema peripheral and peripheral swelling.
- ⁿⁿ includes infusion-related reaction and urticaria with onset on the day of dosing or 1 day after dosing.

Table 4. Adverse drug reactions in patients treated with IMFINZI in combination with tremelimumab

	IMFINZI in combination with tremelimumab 75 mg and platinum-based chemotherapy	IMFINZI in combination with tremelimumab 300 mg
Infections and infestations		
Very common	Upper respiratory tract infections ^a , Pneumonia ^b	
Common	Influenza, Oral candidiasis	Upper respiratory tract infections ^a , Pneumonia ^b , Influenza, Dental and oral soft tissue infections ^c
Uncommon	Dental and oral soft tissue infections ^c	Oral candidiasis
Blood and lymphatic system disorders		
Very Common	Anaemia ^d , Neutropenia ^{d,e} , Thrombocytopenia ^{d,f} , Leukopenia ^{d,g}	
Common	Febrile neutropenia ^d , Pancytopenia ^d	
Uncommon	Immune thrombocytopenia	
Not known		Immune thrombocytopenia ^h
Endocrine disorders		

	IMFINZI in combination with tremelimumab 75 mg and platinum-based chemotherapy	IMFINZI in combination with tremelimumab 300 mg
Very common	Hypothyroidism ⁱ	Hypothyroidism ⁱ
Common	Hyperthyroidism ^j , Adrenal insufficiency, Hypopituitarism/Hypophysitis, Thyroiditis ^k	Hyperthyroidism ^j , Thyroiditis ^k , Adrenal insufficiency
Uncommon	Diabetes insipidus, Type 1 diabetes mellitus	Hypopituitarism/Hypophysitis
Not known		Diabetes insipidus ^h , Type 1 diabetes mellitus ^h
Eye disorders		
Uncommon	Uveitis	
Rare		Uveitis ^h
Metabolism and nutrition disorders		
Very common	Decreased appetite ^d	
Nervous system disorders		
Common	Neuropathy peripheral ^{d,l}	
Uncommon	Encephalitis ^m ,	Myasthenia gravis, Meningitis
Not known	Myasthenia gravis ⁿ , Guillain-Barre syndrome ⁿ , Meningitis ⁿ , Transverse myelitis ^o	Guillain-Barré syndrome ^h , Encephalitis ^h , Transverse myelitis ^o
Cardiac disorders		
Uncommon	Myocarditis ^p	Myocarditis
Respiratory, thoracic, and mediastinal disorders		
Very common	Cough/Productive Cough	Cough/Productive cough
Common	Pneumonitis ^q , Dysphonia	Pneumonitis ^q
Uncommon	Interstitial lung disease	Dysphonia, Intersitial lung disease
Gastrointestinal disorders		
Very common	Nausea ^d , Diarrhoea, Constipation ^d , Vomiting ^d	Diarrhoea, Abdominal pain ^r
Common	Stomatitis ^{d,s} , Amylase increased, Abdominal pain ^r , Lipase increased, Colitis ^t , Pancreatitis ^u	Lipase increased, Amylase increased, Colitis ^t , Pancreatitis ^u
Rare	Coeliac disease ⁿ	Coeliac disease ^h
Not known	Intestinal perforation ⁿ , Large intestine perforation ⁿ	Intestinal perforation ^h , Large intestinal perforation ^h
Hepatobiliary disorders		
Very common	Aspartate aminotransferase increased/Alanine aminotransferase increased ^v	Aspartate aminotransferase increased/Alanine aminotransferase increased ^v
Common	Hepatitis ^w	Hepatitis ^w
Skin and subcutaneous tissue disorders		
Very common	Alopecia ^d , Rash ^x , Pruritus	Rash ^x , Pruritus
Common		Dermatitis ^y , Night sweats,
Uncommon	Dermatitis, Night sweats, Pemphigoid	Pemphigoid
Musculoskeletal and connective tissue disorders		
Very common	Arthralgia	
Common	Myalgia	Myalgia
Uncommon	Myositis ^z , Polymyositis ^z , Immune-mediated arthritis ⁿ	Myositis ^z , Polymyositis ^z , Immune-mediated arthritis, Polymyalgia rheumatica
Not known	Polymyalgia rheumatica ⁿ	
Renal and urinary disorders		
Common	Blood creatinine increased, Dysuria	Blood creatinine increased, Dysuria

	IMFINZI in combination with tremelimumab 75 mg and platinum-based chemotherapy	IMFINZI in combination with tremelimumab 300 mg
Uncommon	Nephritis, Cystitis noninfective	Nephritis ^{aa}
Not known		Cystitis noninfective ^h
General disorders and administration site conditions		
Very common	Fatigue ^d , Pyrexia	Pyrexia, Oedema peripheral ^{bb}
Common	Oedema peripheral ^{bb}	
Injury, poisoning and procedural complications		
Common	Infusion-related reaction ^{cc}	Infusion-related reaction ^{cc}

^a Includes laryngitis, nasopharyngitis, pharyngitis, rhinitis, sinusitis, tonsillitis, tracheobronchitis and upper respiratory tract infection.

^b Includes pneumocystis jirovecii pneumonia, pneumonia and pneumonia bacterial.

^c Includes periodontitis, pulpitis dental, tooth abscess and tooth infection.

^d Adverse reaction only applies to chemotherapy ADRs in the POSEIDON study.

^e Includes neutropenia and neutrophil count decreased.

^f Includes platelet count decreased and thrombocytopenia.

^g Includes leukopenia and white blood cell count decreased.

^h Adverse reaction was not observed in the HCC pool, but was reported in patients treated with IMFINZI or IMFINZI+tremelimumab in AstraZeneca-sponsored clinical studies.

ⁱ Includes blood thyroid stimulating hormone increased, hypothyroidism and immune-mediated hypothyroidism.

^j Includes blood thyroid stimulating hormone decreased and hyperthyroidism.

^k Includes autoimmune thyroiditis, immune-mediated thyroiditis, thyroiditis and thyroiditis subacute.

^l Includes neuropathy peripheral, paraesthesia and peripheral sensory neuropathy.

^m Includes encephalitis and encephalitis autoimmune.

ⁿ Adverse reaction was not observed in the POSEIDON study but was reported in patients treated with IMFINZI or IMFINZI+tremelimumab in clinical studies outside of the POSEIDON dataset.

^o Reported in studies outside of the POSEIDON study and HCC pool.

^p Includes autoimmune myocarditis.

^q Includes immune-mediated pneumonitis and pneumonitis.

^r Includes abdominal pain, abdominal pain lower, abdominal pain upper and flank pain.

^s Includes mucosal inflammation and stomatitis.

^t Includes colitis, enteritis and enterocolitis.

^u Includes autoimmune pancreatitis, pancreatitis and pancreatitis acute.

^v Includes alanine aminotransferase increased, aspartate aminotransferase increased, hepatic enzyme increased and transaminases increased.

^w Includes autoimmune hepatitis, hepatitis, hepatocellular injury, hepatotoxicity, hepatitis acute and immune-mediated hepatitis.

^x Includes eczema, erythema, rash, rash macular, rash maculopapular, rash papular, rash pruritic and rash pustular.

^y Includes dermatitis and immune-mediated dermatitis.

^z Includes rhabdomyolysis, myositis, and polymyositis.

^{aa} Includes autoimmune nephritis and immune-mediated nephritis.

^{bb} Includes oedema peripheral and peripheral swelling.

^{cc} Includes infusion-related reaction and urticaria.

Description of selected adverse reactions

IMFINZI is associated with immune-mediated adverse reactions. Most of these, including severe reactions, resolved following initiation of appropriate medical therapy and/or treatment modifications. The data for the following immune-mediated adverse reactions reflect the IMFINZI monotherapy combined safety database of 4 642 patients which includes the PACIFIC, HIMALAYA and ADRIATIC studies and additional studies in patients with various solid tumours, in indications for which durvalumab is not approved. Across all studies, IMFINZI was administered at a dose of 10 mg/kg every 2 weeks, 20 mg/kg every 4 weeks or 1 500 mg every 3 or 4 weeks. Details for the

significant adverse reactions for IMFINZI when given in combination with chemotherapy are presented if clinically relevant differences were noted in comparison to IMFINZI monotherapy.

The data for the following immune-mediated adverse reactions are also based on 2 280 patients who received IMFINZI 20 mg/kg every 4 weeks in combination with tremelimumab 1 mg/kg or IMFINZI 1 500 mg in combination with tremelimumab 75 mg every 4 weeks. Details for the significant adverse reactions for IMFINZI when given in combination with tremelimumab and platinum-based chemotherapy are presented if clinically relevant differences were noted in comparison to IMFINZI in combination with tremelimumab.

The data for the following immune-mediated adverse reactions also reflect the IMFINZI in combination with tremelimumab 300 mg combined safety database of 462 patients with HCC (the HCC pool). In these two studies, IMFINZI was administered at a dose of 1 500 mg in combination with tremelimumab 300 mg every 4 weeks.

The management guidelines for these adverse reactions are described in section 4.2 and 4.4.

Immune-mediated pneumonitis

In the combined safety database with IMFINZI monotherapy, (n=4 642 multiple tumour types), immune-mediated pneumonitis occurred in 147 (3.2%) patients, including Grade 3 in 37 (0.8%) patients, Grade 4 in 2 (< 0.1%) patients and Grade 5 in 10 (0.2%) patients. The median time to onset was 56 days (range: 1-1 308 days). One hundred and fourteen of the 147 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day) and 4 patients also received other immunosuppressants including infliximab and cyclosporine. IMFINZI was discontinued in 60 patients. Resolution occurred in 85 patients.

Immune-mediated pneumonitis occurred more frequently in patients in the PACIFIC Study who had completed treatment with concurrent chemoradiation within 1 to 42 days prior to initiation of study treatment (10.7%), than in the other patients in the combined safety database (1.0%).

In the PACIFIC Study, (n=475 in the IMFINZI arm, and n=234 in the placebo arm) immune-mediated pneumonitis occurred in 47 (9.9%) patients in the IMFINZI-treated group and 14 (6.0%) patients in the placebo group, including Grade 3 in 9 (1.9%) patients on IMFINZI vs. 6 (2.6%) patients on placebo and Grade 5 (fatal) in 4 (0.8%) patients on IMFINZI vs. 3 (1.3%) patients on placebo. The median time to onset in the IMFINZI-treated group was 46 days (range: 2-342 days) vs. 57 days (range: 26-253 days) in the placebo group. In the IMFINZI-treated group, all patients received systemic corticosteroids, including 30 patients who received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day) and 2 patients also received infliximab. In the placebo group, all patients received systemic corticosteroids, including 12 patients who received high-dose corticosteroid treatment and 1 patient also received cyclophosphamide and tacrolimus. Resolution occurred for 29 patients in the IMFINZI treated group vs. 6 in placebo.

In the ADRIATIC Study, in patients with LS-SCLC (n=262 in the IMFINZI arm, and n=265 in the placebo arm), immune-mediated pneumonitis occurred in 31 (11.8%) patients in the IMFINZI-treated group and 8 (3.0%) patients in the placebo group, including Grade 3 in 5 (1.9%) patients on IMFINZI vs. 1 (0.4%) patient on placebo and Grade 5 (fatal) in 1 (0.4%) patient on IMFINZI. The median time to onset in the IMFINZI-treated group was 55 days (range: 1-375 days) vs. 65.5 days (range: 24-124 days) in the placebo group. In the IMFINZI-treated group all patients received systemic corticosteroids, including 25 patients who received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day) and 1 patient also received infliximab. In the placebo group all patients received systemic corticosteroids, including 7 patients who received high-dose corticosteroid treatment. Resolution occurred for 18 patients in the IMFINZI treated group vs. 3 in placebo.

In the combined safety database with IMFINZI in combination with tremelimumab (n=2 280), immune-mediated pneumonitis occurred in 86 (3.8%) patients, including Grade 3 in 30 (1.3%) patients, Grade 4 in 1 (< 0.1%) patient, and Grade 5 (fatal) in 7 (0.3%) patients. The median time to

onset was 57 days (range: 8 - 912 days). All patients received systemic corticosteroids and 79 of the 86 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Seven patients also received other immunosuppressants. Treatment was discontinued in 39 patients. Resolution occurred in 51 patients.

In the HCC pool (n=462), immune-mediated pneumonitis occurred in 6 (1.3%) patients, including Grade 3 in 1 (0.2%) patient and Grade 5 (fatal) in 1 (0.2%) patient. The median time to onset was 29 days (range: 5-774 days). Six patients received systemic corticosteroids, and 5 of the 6 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). One patient also received other immunosuppressants. Treatment was discontinued in 2 patients. Resolution occurred in 3 patients.

In the DUO-E Study, out of 238 patients treated with platinum-based chemotherapy in combination with IMFINZI, followed by IMFINZI in combination with olaparib (platinum-based chemotherapy + IMFINZI + olaparib arm) immune-mediated pneumonitis occurred in 5 (2.1%) patients, including Grade 3 in 3 (1.3%) patients. The median time to onset was 85 days (range: 65-321 days). Five patients received systemic corticosteroids, including 4 patients who received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Resolution occurred in all 5 patients.

Immune-mediated hepatitis

In the combined safety database with IMFINZI monotherapy, immune-mediated hepatitis occurred in 120 (2.6%) patients, including Grade 3 in 70 (1.5%) patients, Grade 4 in 9 (0.2%) patients and Grade 5 (fatal) in 6 (0.1%) patients. The median time to onset was 36 days (range: 1-644 days). Ninety-four of the 120 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Nine patients also received other immunosuppressants including mycophenolate treatment. IMFINZI was discontinued in 30 patients. Resolution occurred in 56 patients.

In the combined safety database with IMFINZI in combination with tremelimumab (n=2 280), immune-mediated hepatitis occurred in 80 (3.5%) patients, including Grade 3 in 48 (2.1%) patients, Grade 4 in 8 (0.4%) patients and Grade 5 (fatal) in 2 (< 0.1%) patients. The median time to onset was 36 days (range: 1 - 533 days). All patients received systemic corticosteroids and 68 of the 80 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Eight patients also received other immunosuppressants. Treatment was discontinued in 27 patients. Resolution occurred in 47 patients.

In the HCC pool (n=462), immune-mediated hepatitis occurred in 34 (7.4%) patients, including Grade 3 in 20 (4.3%) patients, Grade 4 in 1 (0.2%) patient and Grade 5 (fatal) in 3 (0.6%) patients. The median time to onset was 29 days (range: 13-313 days). All patients received systemic corticosteroids, and 32 of the 34 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Nine patients also received other immunosuppressants. Treatment was discontinued in 10 patients. Resolution occurred in 13 patients.

Immune-mediated colitis

In the combined safety database with IMFINZI monotherapy, immune-mediated colitis or diarrhoea occurred in 79 (1.7%) patients, including Grade 3 in 15 (0.3%) patients and Grade 4 in 2 (< 0.1%) patients. The median time to onset was 72 days (range: 1-920 days). Fifty-five of the 79 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Five patients also received other immunosuppressants including infliximab treatment and mycophenolate. IMFINZI was discontinued in 15 patients. Resolution occurred in 54 patients.

In the combined safety database with IMFINZI in combination with tremelimumab (n=2 280), immune-mediated colitis or diarrhoea occurred in 167 (7.3%) patients, including Grade 3 in 76 (3.3%) patients and Grade 4 in 3 (0.1%) patients. The median time to onset was 57 days range: 3-906 days). All patients received systemic corticosteroids and 151 of the 167 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Twenty-two patients also

received other immunosuppressants. Treatment was discontinued in 54 patients. Resolution occurred in 141 patients.

Intestinal perforation and large intestine perforation were uncommonly reported in patients receiving IMFINZI in combination with tremelimumab.

In the HCC pool (n=462), immune-mediated colitis or diarrhoea occurred in 31 (6.7%) patients, including Grade 3 in 17 (3.7%) patients. The median time to onset was 23 days (range: 2-479 days). All patients received systemic corticosteroids, and 28 of the 31 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Four patients also received other immunosuppressants. Treatment was discontinued in 5 patients. Resolution occurred in 29 patients.

Intestinal perforation was observed in patients receiving IMFINZI in combination with tremelimumab (rare) in studies outside of the HCC pool.

Immune-mediated endocrinopathies

Immune-mediated hypothyroidism

In the combined safety database with IMFINZI monotherapy, immune-mediated hypothyroidism occurred in 384 (8.3%) patients, including Grade 3 in 7 (0.2%) patients. The median time to onset was 90.5 days (range: 1-951 days). Of the 384 patients, 379 patients received hormone replacement therapy and 7 patients received high-dose corticosteroids (at least 40 mg prednisone or equivalent per day) for immune-mediated hypothyroidism. One patient discontinued IMFINZI due to immune-mediated hypothyroidism. Resolution occurred in 79 patients.

In the combined safety database with IMFINZI in combination with tremelimumab (n=2 280), immune-mediated hypothyroidism occurred in 209 (9.2%) patients, including Grade 3 in 6 (0.3%) patients. The median time to onset was 85 days (range: 1-624 days). Thirteen patients received systemic corticosteroids and 8 of the 13 received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Treatment discontinued in 3 patients. Resolution occurred in 52 patients. Immune-mediated hypothyroidism was preceded by immune-mediated hyperthyroidism in 25 patients or immune-mediated thyroiditis in 2 patients.

In the HCC pool (n=462), immune-mediated hypothyroidism occurred in 46 (10.0%) patients. The median time to onset was 85 days (range: 26-763 days). One patient received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). All patients required other therapy including hormone replacement therapy. Resolution occurred in 6 patients. Immune-mediated hypothyroidism was preceded by immune-mediated hyperthyroidism in 4 patients.

Immune-mediated hyperthyroidism

In the combined safety database with IMFINZI monotherapy, immune-mediated hyperthyroidism occurred in 76 (1.6%) patients. The median time to onset was 43 days (range: 1-253 days). Seventy-one of the 76 patients received medical therapy (thiamazole, carbimazole, propylthiouracil, perchlorate, calcium channel blocker or beta-blocker), 15 patients received systemic corticosteroids and 8 of the 15 patients received high-dose systemic corticosteroid treatment (at least 40 mg prednisone or equivalent per day). One patient discontinued IMFINZI due to immune-mediated hyperthyroidism. Resolution occurred in 62 patients. Thirty-one patients experienced hypothyroidism following hyperthyroidism.

In the combined safety database with IMFINZI in combination with tremelimumab (n=2 280), immune-mediated hyperthyroidism occurred in 62 (2.7%) patients, including Grade 3 in 5 (0.2%) patients. The median time to onset was 33 days (range: 4-176 days). Eighteen patients received systemic corticosteroids, and 11 of the 18 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Fifty-three patients required other therapy (thiamazole, carbimazole, propylthiouracil, perchlorate, calcium channel blocker or beta-blocker). One patient discontinued treatment due to hyperthyroidism. Resolution occurred in 47 patients.

In the HCC pool (n=462), immune-mediated hyperthyroidism occurred in 21 (4.5%) patients, including Grade 3 in 1 (0.2%) patient. The median time to onset was 30 days (range: 13-60 days). Four patients received systemic corticosteroids, and all of the four patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Twenty patients required other therapy (thiamazole, carbimazole, propylthiouracil, perchlorate, calcium channel blocker, or beta-blocker). One patient discontinued treatment due to hyperthyroidism. Resolution occurred in 17 patients.

Immune-mediated thyroiditis

In the combined safety database with IMFINZI monotherapy, immune-mediated thyroiditis occurred in 21 (0.5%) patients, including Grade 3 in 2 (< 0.1%) patients. The median time to onset was 57 days (range: 14-217 days). Of the 21 patients, 18 patients received hormone replacement therapy and 3 patients received high-dose corticosteroids (at least 40 mg prednisone or equivalent per day). One patient discontinued IMFINZI due to immune-mediated thyroiditis. Resolution occurred in 8 patients. Five patients experienced hypothyroidism following thyroiditis.

In the combined safety database with IMFINZI in combination with tremelimumab (n=2 280), immune-mediated thyroiditis occurred in 15 (0.7%) patients, including Grade 3 in 1 (< 0.1%) patient. The median time to onset was 57 days (range: 22-141 days). Five patients received systemic corticosteroids and 2 of the 5 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Thirteen patients required other therapy including, hormone replacement therapy, thiamazole, carbimazole, propylthiouracil, perchlorate, calcium channel blocker, or beta-blocker. No patients discontinued treatment due to immune-mediated thyroiditis. Resolution occurred in 5 patients.

In the HCC pool (n=462), immune-mediated thyroiditis occurred in 6 (1.3%) patients. The median time to onset was 56 days (range: 7-84 days). Two patients received systemic corticosteroids, and 1 of the 2 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). All patients required other therapy including hormone replacement therapy. Resolution occurred in 2 patients.

Immune-mediated adrenal insufficiency

In the combined safety database with IMFINZI monotherapy, immune-mediated adrenal insufficiency occurred in 24 (0.5%) patients, including Grade 3 in 8 (0.2%) patients. The median time to onset was 157.5 days (range: 20-547 days). All 24 patients received systemic corticosteroids; 8 of the 24 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). One patient discontinued IMFINZI due to immune-mediated adrenal insufficiency. Resolution occurred in 6 patients.

In the combined safety database with IMFINZI in combination with tremelimumab (n=2 280), immune-mediated adrenal insufficiency occurred in 33 (1.4%) patients, including Grade 3 in 16 (0.7%) patients and Grade 4 in 1 (< 0.1%) patient. The median time to onset was 105 days (range: 20-428 days). Thirty-two patients received systemic corticosteroids, and 10 of the 32 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Treatment was discontinued in one patient. Resolution occurred in 11 patients.

In the HCC pool (n=462), immune-mediated adrenal insufficiency occurred in 6 (1.3%) patients, including Grade 3 in 1 (0.2%) patient. The median time to onset was 64 days (range: 43-504 days). All patients received systemic corticosteroids, and 1 of the 6 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Resolution occurred in 2 patients.

Immune-mediated type 1 diabetes mellitus

In the combined safety database with IMFINZI monotherapy, immune-mediated type 1 diabetes mellitus occurred in 5 (0.1%) patients, including Grade 3 in 3 (0.1%) patients and Grade 4 in 1 (< 0.1%) patient. The time to onset was 43 days (range: 29-631 days). All five patients required

insulin therapy. IMFINZI was permanently discontinued in one patient. One patient recovered and one patient recovered with sequelae.

In the combined safety database with IMFINZI in combination with tremelimumab (n=2 280), immune-mediated type 1 diabetes mellitus occurred in 6 (0.3%) patients, including Grade 3 in 1 (< 0.1%) patient and Grade 4 in 2 (< 0.1%) patients. The median time to onset was 58 days (range: 7-220 days). All patients required insulin. Treatment was discontinued for 1 patient. Resolution occurred in 1 patient.

Immune mediated hypophysitis/hypopituitarism

In the combined safety database with IMFINZI monotherapy, immune-mediated hypophysitis/hypopituitarism occurred in 6 (0.1%) patients, including Grade 3 in 5 (0.1%) patients. The time to onset for the events was 85 days (range: 44-225 days). Three patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day), three patients discontinued IMFINZI due to immune-mediated hypophysitis/hypopituitarism and resolution occurred in 1 patient.

In the combined safety database with IMFINZI in combination with tremelimumab (n=2 280), immune-mediated hypophysitis/hypopituitarism occurred in 16 (0.7%) patients, including Grade 3 in 8 (0.4%) patients. The median time to onset for the events was 123 days (range: 63-388 days). All patients received systemic corticosteroids and 8 of the 16 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Four patients also required endocrine therapy. Treatment was discontinued in 2 patients. Resolution occurred in 7 patients.

In the HCC pool (n=462), immune-mediated hypophysitis/hypopituitarism occurred in 5 (1.1%) patients. The median time to onset for the events was 149 days (range: 27-242 days). Four patients received systemic corticosteroids, and 1 of the 4 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Three patients also required endocrine therapy. Resolution occurred in 2 patients.

Immune-mediated nephritis

In the combined safety database with IMFINZI monotherapy, immune-mediated nephritis occurred in 17 (0.4%) patients, including Grade 3 in 4 (0.1%) patients and Grade 4 in 1 (< 0.1%) patient. The median time to onset was 84 days (range: 4-393 days). Twelve patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day) and 1 patient also received mycophenolate. IMFINZI was discontinued in 7 patients. Resolution occurred in 8 patients.

In the combined safety database with IMFINZI in combination with tremelimumab (n=2 280), immune-mediated nephritis occurred in 9 (0.4%) patients, including Grade 3 in 1 (< 0.1%) patient. The median time to onset was 79 days (range: 39-183 days). All patients received systemic corticosteroids and 7 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Treatment was discontinued in 3 patients. Resolution occurred in 5 patients.

In the HCC pool (n=462), immune-mediated nephritis occurred in 4 (0.9%) patients, including Grade 3 in 2 (0.4%) patients. The median time to onset was 53 days (range: 26-242 days). All patients received systemic corticosteroids, and 3 of the 4 received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Treatment was discontinued in 2 patients. Resolution occurred in 3 patients.

Immune-mediated rash

In the combined safety database with IMFINZI monotherapy, immune-mediated rash or dermatitis (including pemphigoid) occurred in 74 (1.6%) patients, including Grade 3 in 20 (0.4%) patients. The median time to onset was 56 days (range: 4-600 days). Thirty-seven of the 74 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). IMFINZI was discontinued in 5 patients. Resolution occurred in 46 patients.

In the combined safety database with IMFINZI in combination with tremelimumab (n=2 280), immune-mediated rash or dermatitis (including pemphigoid) occurred in 112 (4.9%) patients, including Grade 3 in 17 (0.7%) patients. The median time to onset was 35 days (range: 1-778 days). All patients received systemic corticosteroids, and 57 of the 112 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Treatment was discontinued in 10 patients. Resolution occurred in 65 patients.

In the HCC pool (n=462), immune-mediated rash or dermatitis (including pemphigoid) occurred in 26 (5.6%) patients, including Grade 3 in 9 (1.9%) patients and Grade 4 in 1 (0.2%) patient. The median time to onset was 25 days (range: 2-933 days). All patients received systemic corticosteroids and 14 of the 26 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). One patient received other immunosuppressants. Treatment was discontinued in 3 patients. Resolution occurred in 19 patients.

In the DUO-E Study, out of 238 patients treated with platinum-based chemotherapy in combination with IMFINZI, followed by IMFINZI in combination with olaparib (platinum-based chemotherapy + IMFINZI + olaparib arm) immune-mediated rash occurred in 8 (3.4%) patients, including Grade 3 in 2 (0.8%) patients. The median time to onset was 155 days (range: 2-308 days). All patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Resolution occurred in all 8 patients.

Infusion-related reactions

In the combined safety database with IMFINZI monotherapy, infusion-related reactions occurred in 70 (1.5%) patients, including Grade 3 in 6 (0.1%) patients. There were no Grade 4 or 5 events.

In the combined safety database with IMFINZI in combination with tremelimumab (n=2 280), infusion-related reactions occurred in 45 (2.0%) patients, including Grade 3 in 2 (< 0.1%) patients. There were no Grade 4 or 5 events.

In the DUO-E Study, out of 238 patients treated with platinum-based chemotherapy in combination with IMFINZI, followed by IMFINZI in combination with olaparib (platinum-based chemotherapy + IMFINZI + olaparib arm), infusion-related reactions occurred in 13 (5.5%) patients, including Grade 3 in 1 (0.4%) patient. There were no Grade 4 or 5 events.

Pure Red Cell Aplasia

Pure Red Cell Aplasia (PRCA) has been reported when IMFINZI has been used in combination with olaparib. In a clinical study of patients with endometrial cancer treated with IMFINZI in combination with olaparib, the incidence of PRCA was 1.6%. All events were CTCAE Grade 3 or 4. Events were manageable following discontinuation of both IMFINZI and olaparib. The majority of events were managed with blood transfusion and immunosuppression and recovered; there were no fatal events. For management see section 4.4.

Laboratory abnormalities

In patients treated with IMFINZI monotherapy, the proportion of patients who experienced a shift from baseline to a Grade 3 or 4 laboratory abnormality was as follows: 3.7% for alanine aminotransferase increased, 5.7% for aspartate aminotransferase increased, 0.9% for blood creatinine increased, 4.8% for amylase increased and 8.2% for lipase increased. The proportion of patients who experienced a TSH shift from baseline that was $\leq$ ULN to any grade $>$ ULN was 20% and a TSH shift from baseline that was $\geq$ LLN to any grade $<$ LLN was 18.2%.

In patients treated with IMFINZI in combination with chemotherapy, the proportion of patients who experienced a shift from baseline to a Grade 3 or 4 laboratory abnormality was as follows: 4.2% for alanine aminotransferase increased, 3.4% for aspartate aminotransferase increased, 4.0% for blood creatinine increased, 6.0% for amylase increased, 12.1% for lipase increased, and 2.3% for bilirubin increased. The proportion of patients who experienced a TSH shift from baseline that was $\leq$ ULN to

any grade > ULN was 22.8% and a TSH shift from baseline that was $\geq$ LLN to any grade < LLN was 22.6%.

In patients treated with IMFINZI in combination with tremelimumab and platinum-based chemotherapy, the proportion of patients who experienced a shift from baseline to a Grade 3 or 4 laboratory abnormality was as follows: 6.2% for alanine aminotransferase increased, 5.2% for aspartate aminotransferase increased, 4.0% for blood creatinine increased, 9.4% for amylase increased and 13.6% for lipase increased. The proportion of patients who experienced a TSH shift from baseline that was $\leq$ ULN to > ULN was 24.8% and a TSH shift from baseline that was $\geq$ LLN to < LLN was 32.9%.

In patients treated with IMFINZI in combination with tremelimumab, the proportion of patients who experienced a shift from baseline to a Grade 3 or 4 laboratory abnormality was as follows: 5.1% for alanine aminotransferase increased, 5.8% for aspartate aminotransferase, 1.0% for blood creatinine increased, 5.9% for amylase increased and 11.3% for lipase increased. The proportion of patients who experienced a TSH shift from baseline that was $\leq$ ULN to > ULN was 4.2% and a TSH shift from baseline that was $\geq$ LLN to < LLN was 17.2%.

In patients treated with platinum-based chemotherapy in combination with IMFINZI, followed by IMFINZI in combination with olaparib (platinum-based chemotherapy + IMFINZI + olaparib arm), the proportion of patients who experienced a shift from baseline to a Grade 3 or 4 laboratory abnormality was as follows: 3.8% for alanine aminotransferase increased, 3.4% for aspartate aminotransferase increased and 1.7% for blood creatinine increased. The proportion of patients who experienced a TSH shift from baseline that was $\leq$ ULN to > ULN was 28.6% and a TSH shift from baseline that was $\geq$ LLN to < LLN was 20.1%.

Immunogenicity

Immunogenicity of IMFINZI as monotherapy is based on pooled data in 3 069 patients who were treated with IMFINZI 10 mg/kg every 2 weeks, or 20 mg/kg every 4 weeks as a single-agent and evaluable for the presence of anti-drug antibodies (ADAs). Eighty-four patients (2.7%) tested positive for treatment emergent ADAs. Neutralising antibodies (nAb) against durvalumab were detected in 0.5% (16/3 069) of patients. The presence of ADAs did not have a clinically relevant effect on pharmacokinetics or safety. There are insufficient number of patients to determine ADA impact on efficacy.

Across multiple phase III studies, in patients treated with IMFINZI in combination with other therapeutic agents, 0% to 10.1% of patients developed treatment-emergent ADAs. Neutralizing antibodies against durvalumab were detected in 0% to 1.7% of patients treated with IMFINZI in combination with other therapeutic agents. The presence of ADAs did not have an apparent effect on pharmacokinetics or safety.

Elderly

No overall differences in safety were reported between elderly ($\geq$ 65 years) and younger patients.

In studies PACIFIC, ADRIATIC, CASPIAN, TOPAZ-1, HIMALAYA, NIAGARA, and MATTERHORN data on safety for patients 75 years and older are too limited to draw a conclusion on this population.

In first line metastatic NSCLC patients in the POSEIDON study, some differences in safety were reported between elderly ($\geq$ 65 years) and younger patients. The safety data from patients 75 years of age or older are limited to a total of 74 patients. There was a higher frequency of serious adverse reactions and discontinuation rate of any study treatment due to adverse reactions in 35 patients aged 75 years of age or older treated with IMFINZI in combination with tremelimumab and platinum-based chemotherapy (45.7% and 28.6%, respectively) relative to 39 patients aged 75 years of age or older who received platinum-based chemotherapy only (35.9% and 20.5%, respectively).

In resectable NSCLC patients in the AEGEAN study, some differences in safety were reported between elderly (≥ 65 years) and younger patients. The safety data from patients 75 years of age or older are limited to 86 patients in both treatment arms. There was a higher frequency of serious adverse reactions in patients aged 75 years or older who received IMFINZI in combination with chemotherapy relative to patients who received chemotherapy only (26.5% vs. 10.8%, respectively). There was a higher frequency of discontinuation of any study treatment due to adverse reactions in patients aged 75 years or older who received IMFINZI in combination with chemotherapy relative to patients who received chemotherapy only (16.3% vs. 8.1%, respectively).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:

Ireland

HPRA Pharmacovigilance

Website: www.hpra.ie

Malta

ADR Reporting Website: <https://medicinesauthority.gov.mt/adrportal>

4.9 Overdose

There is no information on overdose with durvalumab. In case of overdose, patients should be closely monitored for signs or symptoms of adverse reactions, and appropriate symptomatic treatment instituted immediately.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antineoplastic agents, monoclonal antibodies and antibody drug conjugates, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors. ATC code: L01FF03.

Mechanism of action

Expression of programmed cell death ligand-1 (PD-L1) protein is an adaptive immune response that helps tumours evade detection and elimination by the immune system. PD-L1 can be induced by inflammatory signals (e.g., IFN-gamma) and can be expressed on both tumour cells and tumour-associated immune cells in tumour microenvironment. PD-L1 blocks T-cell function and activation through interaction with PD-1 and CD80 (B7.1). By binding to its receptors, PD-L1 reduces cytotoxic T-cell activity, proliferation and cytokine production.

Durvalumab is a fully human, immunoglobulin G1 kappa (IgG1 κ) monoclonal antibody that selectively blocks the interaction of PD-L1 with PD-1 and CD80 (B7.1). Durvalumab does not induce antibody dependent cell-mediated cytotoxicity (ADCC). Selective blockade of PD-L1/PD-1 and PD-L1/CD80 interactions enhances antitumour immune responses and increases T-cell activation.

The combination of tremelimumab, a CTLA-4 inhibitor and durvalumab, a PD-L1 inhibitor functions to enhance anti-tumour T-cell activation and function at multiple stages of the immune response resulting in improved anti-tumour responses. In murine syngeneic tumour models, dual blockade of PD-L1 and CTLA-4 resulted in enhanced anti-tumour activity.

Clinical efficacy and safety

Durvalumab doses of 10 mg/kg every 2 weeks, 1 120 mg every 3 weeks or 1 500 mg every 4 weeks were evaluated in NSCLC, ES-SCLC and endometrial cancer clinical studies. Based on the modeling

and simulation of exposure, exposure-safety relationships and exposure-efficacy data comparisons, there are no anticipated clinically significant differences in efficacy and safety between durvalumab doses of 10 mg/kg every 2 weeks, 120 mg every 3 weeks or 500 mg every 4 weeks.

Resectable NSCLC – AEGEAN Study

AEGEAN was a randomised, double-blind, placebo-controlled, multicentre, Phase III study designed to evaluate the efficacy of IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, then continued as IMFINZI monotherapy after surgery, in patients with resectable NSCLC.

The following selection criteria define patients with high risk of recurrence who are included in the therapeutic indication and are reflective of a patient population with Stage IIA to select Stage IIIB as per the AJCC/UICC, 8th edition staging system:

- any patient with a tumour size ≥ 4 cm;
- any patient with N1 or N2 disease (regardless of primary tumour size), including multi-station N2 disease;
- patients with multiple tumour nodules in the same lobe or tumours that involve the main bronchus or tumours that invade visceral pleura, chest wall (including the parietal pleura and superior sulcus tumours), phrenic nerve or parietal pericardium; or tumours that are associated with atelectasis or obstructive pneumonitis that extends to the hilar region or involves part or all of the lung.

The study enrolled previously untreated patients with documented squamous or non-squamous NSCLC and no prior exposure to immune-mediated therapy, a WHO/ECOG Performance status of 0 or 1, and at least one RECIST 1.1 target lesion. Prior to randomisation, patients had tumour PD-L1 expression status confirmed using the VENTANA PD-L1 (SP263) Assay.

The study excluded patients with active or prior documented autoimmune disease, or use of immunosuppressive medication within 14 days of the first dose of durvalumab. The study population for efficacy analysis (modified intent-to-treat [mITT]) excluded patients with known EGFR mutations or ALK rearrangements. Following a protocol amendment, local ALK testing (unless squamous histology) and central EGFR testing was mandated. There were 51 patients with EGFR mutations and 11 patients with ALK rearrangements randomised into and treated within the study; however, these patients were not included in the mITT efficacy analysis and robust conclusions cannot be drawn regarding patients with EGFR mutations or ALK rearrangements.

Randomisation was stratified by disease stage (Stage II vs. Stage III) and by PD-L1 expression (TC $< 1\%$ vs. TC $\geq 1\%$) status.

Post-operative radiotherapy (PORT) was permitted for patients for whom it was indicated according to local guidance. PORT was to be started within 8 weeks of surgery and adjuvant durvalumab/placebo must then have been started within 3 weeks of the completion of PORT.

The AEGEAN study randomised 802 patients in a 1:1 ratio to receive perioperative IMFINZI (Arm 1) or placebo (Arm 2) in combination with neoadjuvant chemotherapy. Crossover between the study arms was not permitted.

- Arm 1: IMFINZI 500 mg + chemotherapy every 3 weeks for up to 4 cycles prior to surgery, followed by IMFINZI 500 mg every 4 weeks for up to 12 cycles after surgery.
- Arm 2: Placebo + chemotherapy every 3 weeks for up to 4 cycles prior to surgery, followed by Placebo every 4 weeks for up to 12 cycles after surgery.

In the 2 treatment arms, patients received one of the following histology-based chemotherapy regimens:

- Squamous NSCLC
 - Carboplatin + paclitaxel: carboplatin AUC 6 and paclitaxel 200 mg/m² via IV infusion on Day 1 of each 3-week cycle, for 4 cycles.
- Squamous NSCLC

- Cisplatin + gemcitabine: cisplatin 75 mg/m² via IV infusion on Day 1 of each 3-week cycle, for 4 cycles, and gemcitabine 1250 mg/m² via IV infusion on Day 1 and Day 8 of each 3-week cycle, for 4 cycles.
- Non-squamous NSCLC
 - Pemetrexed + cisplatin: pemetrexed 500 mg/m² and cisplatin 75 mg/m² via IV infusion on Day 1 of each 3-week cycle, for 4 cycles.
- Non-squamous NSCLC
 - Pemetrexed + carboplatin: pemetrexed 500 mg/m² and carboplatin AUC 5 via IV infusion on Day 1 of each 3-week cycle, for 4 cycles.

In the event of unfavourable tolerability, patients could switch from cisplatin to carboplatin therapy at any point and in patients with comorbidities or unable to tolerate cisplatin per Investigators judgement, carboplatin AUC 5 could be administered from cycle 1.

A RECIST 1.1 tumour assessment was performed at baseline, and upon completion of the neoadjuvant period (prior to surgery). The first post-surgical CT/MRI scan of the chest and abdomen (including the entire liver and both adrenals) was acquired 5 weeks $\pm$ 2 weeks after surgery and prior to, but as close as possible to the start of adjuvant therapy. Tumour assessments were then conducted every 12 weeks (relative to the date of surgery) until week 48, every 24 weeks (relative to the date of surgery) until week 192 (approximately 4 years), and then every 48 weeks (relative to the date of surgery) thereafter until RECIST 1.1 defined radiological PD, consent withdrawal, or death. Survival assessments were conducted at month 2, 3, and 4 following treatment discontinuation and then every 2 months until month 12 followed by every 3 months.

The primary endpoints of the study were pathological complete response (pCR) by blinded central pathology review, and event-free survival (EFS) by blinded independent central review (BICR) assessment. OS was a key secondary endpoint.

Efficacy analysis was conducted based on 740 patients in the mITT population: 366 patients in Arm 1 and 374 patients in Arm 2. Baseline demographics and disease characteristics of the population were as follows: male (71.6%), female (28.4%), age $\geq$ 65 years (51.6%), median age 65 years (range: 30 to 88), WHO/ECOG PS 0 (68.4%), WHO/ECOG PS 1 (31.6), White (53.6%), Asian (41.5%), Black or African American (0.9%), American Indian or Alaska Native (1.4%), Other Race (2.6%), Hispanic or Latino (16.1%), Not Hispanic or Latino (83.9%), current or past smokers (85.5%), never smoker (14.5%), squamous histology (48.6%) and non-squamous histology (50.7%), Stage II (28.4%), Stage III (71.6%), PD-L1 expression status TC $\geq$ 1% (66.6%), PD-L1 expression status TC < 1% (33.4%).

In the mITT population, there were 295 (80.6%) patients in Arm 1 who underwent curative intent surgery compared to 302 (80.7%) patients in Arm 2. The number of patients who underwent PORT were 26 (7.1%) in Arm 1 and 24 (6.4%) in Arm 2.

At the primary (pre-specified) EFS analysis (DCO: 10 November 2022), with a maturity of 31.9% and a median EFS follow-up in censored patients of 11.7 months, the study showed a statistically significant improvement in the IMFINZI arm compared to the placebo arm [HR=0.68 (95% CI: 0.53, 0.88), p=0.003902].

At the updated (pre-specified) EFS analysis (DCO: 10 May 2024), the median EFS follow-up in censored patients was 25.9 months. At this analysis, OS was not formally tested for statistical significance; the HR for OS was 0.89 (95% CI: 0.70, 1.14) for IMFINZI arm compared to the placebo arm.

Table 5. Efficacy Results for the AEGEAN Study (mITT)

	IMFINZI + chemotherapy (N=366)	Placebo + chemotherapy (N=374)
EFS ^{a,c}		


	IMFINZI + chemotherapy (N=366)	Placebo + chemotherapy (N=374)
Number of events, n (%)	124 (33.9)	165 (44.1)
Median EFS (95% CI) (months)	NR (42.3, NR)	30 (20.6, NR)
Hazard ratio (95% CI)	0.69 (0.55, 0.88)	
pCR ^{a,b,c}		
Number of patients with response	63	16
Response rate, % (95% CI)	17.21 (13.49, 21.48)	4.28 (2.46, 6.85)
Difference in proportions, % (95% CI)	12.96 (8.67, 17.57)	

^a Results are based on updated (pre-specified) EFS analysis (DCO: 10 May 2024) and pCR final analysis (DCO: 10 November 2022).

^b Based on a pre-specified pCR interim analysis (DCO: 14 January 2022) in n=402, the pCR rate was statistically significant (p=0.000036) compared to significance level of 0.0082%.

^c The 2-sided p-value for pCR was calculated based on a stratified CMH test. The 2-sided p-value for EFS was calculated based on a stratified log-rank test. Stratification factors included baseline PD-L1 and disease stage. The boundary for declaring statistical significance for each of the efficacy endpoints were determined by a Lan-DeMets alpha spending function that approximates an O'Brien Fleming approach (EFS=0.9899%, pCR=0.0082%, 2-sided).

Figure 1. Kaplan-Meier Curve of updated EFS analysis (DCO: 10 May 2024)



NSCLC – PACIFIC Study

The efficacy of IMFINZI was evaluated in the PACIFIC Study, a randomised, double-blind, placebo-controlled, multicentre study in 713 patients with locally advanced, unresectable NSCLC. Patients had completed at least 2 cycles of definitive platinum-based chemotherapy with radiation therapy within 1 to 42 days prior to initiation of the study and had a ECOG performance status of 0 or 1. Ninety-two percent of patients had received a total dose of 54 to 66 Gy of radiation. The study excluded patients who had progressed following chemoradiation therapy, patients with prior exposure to any anti-PD-1 or anti-PD-L1 antibody, patients with active or prior documented autoimmune disease within 2 years of initiation of the study; a history of immunodeficiency; a history of severe immune-mediated adverse reactions; medical conditions that required systemic immunosuppression, except physiological dose of systemic corticosteroids; active tuberculosis or hepatitis B or C or HIV

infection or patients receiving live attenuated vaccine within 30 days before or after the start of IMFINZI. Patients were randomised 2:1 to receive 10 mg/kg IMFINZI (n=476) or 10 mg/kg placebo (n=237) via intravenous infusion every 2 weeks for up to 12 months or until unacceptable toxicity or confirmed disease progression. Randomisation was stratified by gender, age (< 65 years vs. ≥ 65 years) and smoking status (smoker vs. non-smoker). Patients with disease control at 12 months were given the option to be re-treated upon disease progression. Tumour assessments were conducted every 8 weeks for the first 12 months and then every 12 weeks thereafter.

Patients were enrolled regardless of their tumour PD-L1 expression level. Where available, archival tumour tissue specimens taken prior to chemoradiation therapy were retrospectively tested for PD-L1 expression on tumour cells (TC) using the VENTANA PD-L1 (SP263) IHC assay. Of the 713 patients randomised, 63% of patients provided a tissue sample of sufficient quality and quantity to determine PD-L1 expression and 37% were unknown.

The demographics and baseline disease characteristics were well balanced between study arms. Baseline demographics of the overall study population were as follows: male (70%), age ≥ 65 years (45%), age ≥ 75 years (8%), White (69%), Asian (27%), other (4%), current smoker (16%), past-smoker (75%), never smoker (9%), ECOG Performance Status 0 (49%), ECOG Performance Status 1 (51%). Disease characteristics were as follows: Stage IIIA (53%), Stage IIIB (45%), histological sub-groups of squamous (46%), non-squamous (54%). Of 451 patients with PD-L1 expression available, 67% were TC ≥ 1% [PD-L1 TC 1-24% (32%), PD-L1 TC ≥ 25% (35%)] and 33% were TC < 1%.

The two primary endpoints of the study were progression-free survival (PFS) and overall survival (OS) of IMFINZI vs. placebo. Secondary efficacy endpoints included PFS at 12 months (PFS 12) and 18 months (PFS 18) from randomisation and Time from Randomisation to Second Progression (PFS2). PFS was assessed by Blinded Independent Central Review (BICR) according to RECIST v1.1.

The study demonstrated a statistically significant improvement in PFS in the IMFINZI-treated group compared with the placebo group [hazard ratio (HR)=0.52 (95% CI: 0.42, 0.65), $p < 0.0001$]. The study demonstrated a statistically significant improvement in OS in the IMFINZI-treated group compared with the placebo group [HR=0.68 (95% CI: 0.53, 0.87), $p=0.00251$].

In the 5-year follow-up analysis, with a median follow-up of 34.2 months, IMFINZI continued to demonstrate improved OS and PFS compared to placebo. The OS and PFS results from the primary analysis and the follow-up analysis are summarized in Table 6.

Table 6. Efficacy results for the PACIFIC Study

	Primary analysis^a		5-year follow-up analysis^b	
	IMFINZI (n=476)	Placebo (n=237)	IMFINZI (n=476)	Placebo (n=237)
OS				
Number of deaths (%)	183 (38.4%)	116 (48.9%)	264 (55.5%)	155 (65.4%)
Median (months) (95% CI)	NR (34.7, NR)	28.7 (22.9, NR)	47.5 (38.1, 52.9)	29.1 (22.1, 35.1)
HR (95% CI)	0.68 (0.53, 0.87)		0.72 (0.59, 0.89)	
2- sided p-value	0.00251			
OS at 24 months (%) (95% CI)	66.3% (61.7%, 70.4%)	55.6% (48.9%, 61.3%)	66.3% (61.8%, 70.4%)	55.3% (48.6%, 61.4%)
p-value	0.005			
OS at 48 months (%) (95% CI)			49.7% (45.0%, 54.2%)	36.3% (30.1%, 42.6%)
OS at 60 months (%) (95% CI)			42.9% (38.2%, 47.4%)	33.4% (27.3%, 39.6%)
PFS				

	Primary analysis^a		5-year follow-up analysis^b	
	IMFINZI (n=476)	Placebo (n=237)	IMFINZI (n=476)	Placebo (n=237)
Number of events (%)	214 (45.0%)	157 (66.2%)	268 (56.3%)	175 (73.8%)
Median PFS (months) (95% CI)	16.8 (13.0, 18.1)	5.6 (4.6, 7.8)	16.9 (13.0, 23.9)	5.6 (4.8, 7.7)
HR (95% CI)	0.52 (0.42, 0.65)		0.55 (0.45, 0.68)	
p-value	p < 0.0001			
PFS at 12 months (%) (95% CI)	55.9% (51.0%, 60.4%)	35.3% (29.0%, 41.7%)	55.7% (51.0%, 60.2%)	34.5% (28.3%, 40.8%)
PFS at 18 months (%) (95% CI)	44.2% (37.7%, 50.5%)	27.0% (19.9%, 34.5%)	49.1% (44.2%, 53.8%)	27.5% (21.6%, 33.6%)
PFS at 48 months (%) (95% CI)			35.0% (29.9%, 40.1%)	19.9% (14.4%, 26.1%)
PFS at 60 months (%) (95% CI)			33.1% (28.0%, 38.2%)	19.0% (13.6%, 25.2%)
PFS2^c				
Median PFS2 (months) (95% CI)	28.3 (25.1, 34.7)	17.1 (14.5, 20.7)		
HR (95% CI)	0.58 (0.46, 0.73)			
p-value	p < 0.0001			

^a Primary analysis of PFS at data cut-off 13 February 2017. Primary analysis of OS and PFS2 at data cut-off 22 March 2018.


^b Follow-up OS and PFS analysis at data cut-off 11 January 2021.

^c PFS2 is defined as the time from the date of randomisation until the date of second progression (defined by local standard clinical practice) or death.

NR: Not Reached

Kaplan-Meier curves for OS and PFS from the 5-year follow-up analysis are presented in Figures 2 and 3.


Figure 2. Kaplan-Meier curve of OS



Number of patients at risk

Month	0	3	6	9	12	15	18	21	24	27	30	33	36	39	42	45	48	51	54	57	60	63	66	69	72	75
IMFINZI	476	464	431	414	385	364	343	319	298	289	273	264	252	241	236	227	218	207	196	183	134	91	40	18	2	0
Placebo	237	220	199	179	171	156	143	133	123	116	107	99	97	93	91	83	78	77	74	72	56	33	16	7	2	0

Figure 3. Kaplan-Meier curve of PFS



Number of patients at risk

Month	0	3	6	9	12	15	18	21	24	27	30	33	36	39	42	45	48	51	54	57	60	63	66	69	72
IMFINZI	476	377	301	267	215	190	165	147	137	128	119	110	103	97	92	85	81	78	67	57	34	22	11	5	0
Placebo	237	164	105	87	68	56	48	41	37	36	30	27	26	25	24	24	22	21	19	19	14	6	4	1	0


The improvements in PFS and OS in favour of patients receiving IMFINZI compared to those receiving placebo were consistently observed in all predefined subgroups analysed, including ethnicity, age, gender, smoking history, EGFR mutation status and histology.

Post-hoc subgroup analysis by PD-L1 expression

Additional subgroup analyses were conducted to evaluate the efficacy by tumour PD-L1 expression ($\geq 25\%$, 1-24%, $\geq 1\%$, $< 1\%$) and for patients whose PD-L1 status cannot be established (PD-L1

unknown). PFS and OS results from the 5-year follow-up analysis are summarised in Figures 4, 5, 6 and 7.


Figure 4. Kaplan-Meier curve of OS for PD-L1 TC $\geq 1\%$



Number of patients at risk

Month	0	3	6	9	12	15	18	21	24	27	30	33	36	39	42	45	48	51	54	57	60	63	66	69	72	75
IMFINZI	212	208	193	186	178	171	165	156	146	141	132	129	124	118	117	114	109	105	103	98	74	52	29	14	1	0
Placebo	91	81	75	67	64	58	52	47	45	44	41	38	38	37	36	33	31	31	30	29	24	14	8	5	2	0

Figure 5. Kaplan-Meier curve of PFS for PD-L1 TC $\geq 1\%$



Number of patients at risk

Month	0	3	6	9	12	15	18	21	24	27	30	33	36	39	42	45	48	51	54	57	60	63	66	69	72
IMFINZI	212	175	142	127	107	95	82	70	67	63	57	55	50	47	45	42	39	38	34	31	22	15	8	4	0
Placebo	91	59	38	34	26	22	19	16	15	15	12	11	10	10	9	9	9	9	8	8	7	2	1	1	0

Figure 6. Forest plot of OS by PD-L1 expression





Figure 7. Forest plot of PFS by PD-L1 expression



Overall the safety profile of durvalumab in PD-L1 TC $\geq 1\%$ subgroup was consistent with the intent to treat population, as was the PD-L1 TC $< 1\%$ subgroup.

Patient-reported outcomes (PRO)

Patient-reported symptoms, function and health-related quality of life (HRQoL) were collected using the EORTC QLQ-C30 and its lung cancer module (EORTC QLQ-LC13). The LC13 and C30 were assessed at baseline, every 4 weeks for the first 8 weeks, followed by every 8 weeks until completion of the treatment period or discontinuation of IMFINZI due to toxicity or disease progression.

Compliance was similar between the IMFINZI and placebo treatment groups (83% vs. 85.1% overall of evaluable forms completed).

At baseline, no differences in patient-reported symptoms, function and HRQoL were observed between IMFINZI and placebo groups. Throughout the duration of the study to Week 48, there was no clinically meaningful difference between IMFINZI and placebo groups in symptoms, functioning and HRQoL (as assessed by a difference of greater than or equal to 10 points).

NSCLC – POSEIDON Study

POSEIDON was a study designed to evaluate the efficacy of IMFINZI with or without tremelimumab in combination with platinum-based chemotherapy. POSEIDON was a randomised, open-label, multi-centre study in 1013 metastatic NSCLC patients with no sensitising epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Patients with histologically or cytologically documented metastatic NSCLC were eligible for enrolment. Patients had no prior chemotherapy or any other systemic therapy for metastatic NSCLC. Prior to randomisation, patients had tumour PD-L1 status confirmed by using the Ventana PD-L1 (SP263) assay. Patients had a World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrolment.

The study excluded patients with active or prior documented autoimmune disease; active and/or untreated brain metastases; a history of immunodeficiency; administration of systemic immunosuppression within 14 days before the start of IMFINZI or tremelimumab, except physiological dose of systemic corticosteroids; active tuberculosis or hepatitis B or C or HIV infection; or patients receiving live attenuated vaccine within 30 days before or after the start of IMFINZI and/or tremelimumab (see section 4.4).

Randomisation was stratified by tumour cells (TC) PD-L1 expression ($TC \geq 50\%$ vs. $TC < 50\%$), disease stage (Stage IVA vs. Stage IVB, per the 8th edition of American Joint Committee on Cancer), and histology (non-squamous vs. squamous).

Patients were randomised 1:1:1 to receive:

- Arm 1: IMFINZI 1 500 mg with tremelimumab 75 mg and platinum-based chemotherapy every 3 weeks for 4 cycles followed by, IMFINZI 1 500 mg every 4 weeks as monotherapy. A fifth dose of tremelimumab 75 mg was given at Week 16 alongside IMFINZI dose 6.
- Arm 2: IMFINZI 1 500 mg and platinum-based chemotherapy every 3 weeks for 4 cycles, followed by IMFINZI 1 500 mg every 4 weeks as monotherapy.
- Arm 3: Platinum-based chemotherapy every 3 weeks for 4 cycles. Patients could receive 2 additional cycles (a total of 6 cycles post-randomisation), as clinically indicated, at the Investigator's discretion.

In the 3 treatment arms, patients received one of the following histology-based chemotherapy regimens:

- Non-squamous NSCLC
 - Pemetrexed 500 mg/m² with carboplatin AUC 5-6 or cisplatin 75 mg/m² every 3 weeks. Unless contraindicated by the investigator, pemetrexed maintenance could be given.
- Squamous NSCLC
 - Gemcitabine 1 000 or 1 250 mg/m² on Days 1 and 8 with cisplatin 75 mg/m² or carboplatin AUC 5-6 on Day 1 every 3 weeks.
- Non-squamous or squamous NSCLC

- Nab-paclitaxel 100 mg/m² on Days 1, 8, and 15 with carboplatin AUC 5-6 on Day 1 every 3 weeks.

Tremelimumab was given up to a maximum of 5 doses unless there was disease progression or unacceptable toxicity. IMFINZI and histology-based pemetrexed maintenance therapy (when applicable) was continued until disease progression or unacceptable toxicity.

Tumour assessments were conducted at Week 6 and Week 12 from the date of randomisation, and then every 8 weeks until confirmed objective disease progression. Survival assessments were conducted every 2 months following treatment discontinuation.

The dual primary endpoints of the study were PFS and OS for IMFINZI + platinum-based chemotherapy vs. platinum-based chemotherapy alone. The key secondary endpoints of the study were PFS and OS for IMFINZI + tremelimumab + platinum-based chemotherapy and platinum-based chemotherapy alone. The secondary endpoints included objective response rate (ORR) and Duration of Response (DoR). PFS, ORR, and DoR, were assessed using BICR according to RECIST v1.1.

The demographics and baseline disease characteristics were well-balanced between study arms. Baseline demographics of the overall study population were as follows: male (76.0%), age $\geq$ 65 years (47.1%), age $\geq$ 75 years (11.3%) median age 64 years (range: 27 to 87 years), White (55.9%), Asian (34.6%), Black or African American (2.0%), Other (7.6%), non-Hispanic or Latino (84.2%), current smoker or past-smoker (78.0%), WHO/ECOG PS 0 (33.4%), WHO/ECOG PS 1 (66.5%). Disease characteristics were as follows: Stage IVA (50.0%), Stage IVB (49.6%), histological sub-groups of squamous (36.9%), non-squamous (62.9%), brain metastases (10.5%), PD-L1 expression TC $\geq$ 50% (28.8%), PD-L1 expression TC < 50% (71.1%).

The study showed a statistically significant improvement in OS with IMFINZI + tremelimumab + platinum-based chemotherapy vs. platinum-based chemotherapy. IMFINZI + tremelimumab + platinum-based chemotherapy showed a statistically significant improvement in PFS vs. platinum-based chemotherapy alone. The results are summarised below.

Table 7. Efficacy results for the POSEIDON study

	Arm 1: IMFINZI+tremelimumab +platinum-based chemotherapy (n=338)	Arm 3: Platinum-based chemotherapy (n=337)
OS ^a		
Number of deaths (%)	251 (74.3)	285 (84.6)
Median OS (months) (95% CI)	14.0 (11.7, 16.1)	11.7 (10.5, 13.1)
HR (95% CI) ^b	0.77 (0.650, 0.916)	
p-value ^c	0.00304	
PFS ^a		
Number of events (%)	238 (70.4)	258 (76.6)
Median PFS (months) (95% CI)	6.2 (5.0, 6.5)	4.8 (4.6, 5.8)
HR (95% CI) ^b	0.72 (0.600, 0.860)	
p-value ^c	0.00031	
ORR n (%) ^{d,e}	130 (38.8)	81 (24.4)
Complete Response n (%)	2 (0.6)	0
Partial Response n (%)	128 (38.2)	81 (24.4)
Median DoR (months) (95% CI) ^{d,e}	9.5 (7.2, NR)	5.1 (4.4, 6.0)

^a Analysis of PFS at data cut off 24 July 2019 (median follow-up 10.15 months). Analysis of OS at data cut off 12 March 2021 (median follow-up 34.86 months). The boundaries for declaring efficacy (Arm 1 vs. Arm 3: PFS 0.00735, OS 0.00797; 2-sided) were determined by a Lan-DeMets alpha spending function that approximates an O'Brien Fleming approach. PFS was assessed by BICR according to RECIST v1.1.

^b HR are derived using a Cox pH model stratified by PD-L1, histology and disease stage.
^c 2-sided p-value based on a log-rank test stratified by PD-L1, histology and disease stage.
^d Confirmed Objective Response.
^e Post-hoc analysis.
 NR=Not Reached, CI=Confidence Interval

Figure 8. Kaplan-Meier curve of OS




Figure 9. Kaplan-Meier curve of PFS





Figure 10 summarises efficacy results of OS by tumour PD-L1 expression in prespecified subgroup analyses.

Figure 10. Forest plot of OS by PD-L1 expression for IMFINZI+tremelimumab+platinum-based chemotherapy vs. platinum-based chemotherapy



Elderly population

A total of 75 patients aged ≥ 75 years were enrolled in the IMFINZI in combination with tremelimumab and chemotherapy (n=35) and platinum-based chemotherapy only (n=40) arms of the POSEIDON study. An exploratory HR of 1.05 (95% CI: 0.64, 1.71) for OS was observed for the IMFINZI in combination with tremelimumab and platinum-based chemotherapy vs. platinum-based chemotherapy within this study subgroup. Due to the exploratory nature of this subgroup analysis no definitive conclusions can be drawn, but caution is suggested when considering this regimen for elderly patients.

SCLC – ADRIATIC Study

ADRIATIC was a study designed to evaluate the efficacy of IMFINZI with or without tremelimumab. ADRIATIC was a randomised, double-blind, placebo-controlled, multicentre study in 730 patients with histologically or cytologically confirmed LS-SCLC (Stage I to III according to AJCC, 8th edition) who had not progressed following concurrent chemoradiation therapy. Patients who were Stage I or II had to be medically inoperable as determined by the investigator. Patients completed 4 cycles of definitive platinum-based chemoradiation, 60-66 Gy once daily (QD) over 6 weeks or 45 Gy twice daily (BID) over 3 weeks, within 1 to 42 days prior to the first dose of study treatment. Prophylactic cranial irradiation (PCI) could be delivered at the discretion of the investigator after chemoradiation therapy and within 1 to 42 days prior to the first dose of study treatment. Patients had a WHO/ECOG performance status of 0 or 1 at enrolment.

The study excluded patients with active or prior documented autoimmune disease within 5 years of initiation of the study; a history of active primary immunodeficiency; a history of Grade ≥ 2 pneumonitis or active tuberculosis or hepatitis B or C or HIV infection and patients with active interstitial lung disease. Patients with mixed SCLC and NSCLC histology were also excluded.

Randomisation was stratified by stage (I/II vs. III) and receipt of PCI (yes vs. no). Patients were randomised 1:1:1 to receive:

- Arm 1: IMFINZI 1 500 mg + placebo every 4 weeks for 4 cycles, followed by IMFINZI 1 500 mg every 4 weeks.
- Arm 2: Placebo + a second placebo every 4 weeks for 4 cycles, followed by a single placebo every 4 weeks.

- Arm 3: IMFINZI 1 500 mg + tremelimumab 75 mg every 4 weeks for 4 cycles, followed by IMFINZI 1 500 mg every 4 weeks.

Once 600 patients had been randomised across all three arms, randomisation to arm 3 was complete and the subsequent 130 patients were randomised 1:1 to either arm 1 or 2, and received either IMFINZI 1 500 mg every 4 weeks or placebo every 4 weeks.

Treatment continued until disease progression, until unacceptable toxicity, or for a maximum of 24 months. Tumour assessments were conducted every 8 weeks for the first 72 weeks, then every 12 weeks up to 96 weeks and then every 24 weeks thereafter.

The demographics and baseline disease characteristics were well balanced between study arms. Baseline demographics and disease characteristics of the IMFINZI and placebo arms were as follows: male (69.1%), age ≥ 65 years (39.2%), White (50.4%), Black or African-American (0.8%), Asian (47.5%), other (1.3%), Hispanic or Latino (4.2%), current smoker (22.3%), past-smoker (68.5%), never smoker (9.2%), WHO/ECOG PS 0 (48.7%), WHO/ECOG PS 1 (51.3%), Stage I (3.6%), Stage II (9.1%), Stage III (87.4%).

Prior to randomisation, all patients received platinum-based chemotherapy (66.2% cisplatin-etoposide, 33.8% carboplatin-etoposide); 72.1% of patients received RT QD (of which 92.4% received ≥ 60 – ≤ 66 Gy QD); 27.9% received RT BID (of which 96.6% received 45 Gy BID) and 53.8% of patients received PCI. Response to CRT was as follows: complete response (12.3%), partial response (73.8%), stable disease (14.0%).

The dual primary endpoints of the study were OS and PFS of IMFINZI vs. placebo. Secondary efficacy endpoints included ORR of IMFINZI vs. placebo. PFS and ORR were assessed by BICR according to RECIST v1.1.

At a planned interim analysis, the study demonstrated a statistically significant improvement in OS and PFS for IMFINZI compared with placebo. See Table 8 and Figures 11 and 12.

Table 8. Efficacy results for the ADRIATIC study

	Arm 1: IMFINZI (n=264)	Arm 2: Placebo (n=266)
OS^a		
Number of deaths (%)	115 (43.6)	146 (54.9)
Median OS (months) (95% CI) ^b	55.9 (37.3, NR)	33.4 (25.5, 39.9)
HR (95% CI) ^c	0.73 (0.569, 0.928)	
p-value ^d	0.01042	
PFS^e		
Number of events (%)	139 (52.7)	169 (63.5)
Median PFS (months) (95% CI) ^b	16.6 (10.2, 28.2)	9.2 (7.4, 12.9)
HR (95% CI) ^f	0.76 (0.606, 0.950)	
p-value ^d	0.01608	

^a Median duration of OS follow-up in censored patients was 37.19 months in the IMFINZI arm and 37.24 months in the placebo arm.

^b Calculated using the Kaplan Meier technique. CI for median derived based on Brookmeyer-Crowley method.

^c The analysis for HR was performed using a stratified Cox proportional hazards model and the 2-sided p-value is based on a stratified log-rank test, both are adjusted for receipt of PCI.


^d p-value based on the results from the pre-planned interim analysis. Based on a Lan-DeMets alpha spending function O'Brien Fleming type boundary and the actual number of events observed, the boundary for declaring

statistical significance for OS was 0.01679 for a 4.5% overall alpha and for PFS was 0.02805 for a 5% overall alpha (Lan^oand^oDeMets 1983).

^e Assessed by BICR according to RECIST v1.1.


^f The analysis for HR was performed using a stratified Cox proportional hazards model and the 2-sided p-value is based on a stratified log-rank test, both are adjusted for TNM stage and receipt of PCI.

Figure 11: Kaplan-Meier Curve of OS



Number of patients at risk																						
	0	3	6	9	12	15	18	21	24	27	30	33	36	39	42	45	48	51	54	57	60	63
IMFINZI	264	261	248	236	223	207	189	183	172	162	141	110	90	68	51	39	27	19	11	5	1	0
Placebo	266	260	247	231	214	195	175	164	151	143	123	97	80	62	44	31	23	19	8	5	1	0

Figure 12: Kaplan-Meier Curve of PFS



Number of patients at risk																	
	0	3	6	9	12	15	18	21	24	27	30	33	36	39	42	45	48
IMFINZI	264	212	161	135	113	105	101	98	84	78	51	51	33	21	19	10	10
Placebo	266	208	146	122	100	88	79	76	71	69	47	47	34	23	22	15	14

SCLC – CASPIAN Study

CASPIAN was a study designed to evaluate the efficacy of IMFINZI with or without tremelimumab in combination with etoposide and either carboplatin or cisplatin. CASPIAN was a randomised, open-label, multicentre study in 805 treatment naïve ES-SCLC patients with WHO/ECOG Performance status of 0 or 1, body weight > 30 kg, suitable to receive a platinum-based chemotherapy regimen as first-line treatment for SCLC, with life expectancy ≥ 12 weeks, at least one target lesion by RECIST 1.1 and adequate organ and bone marrow function. Patients with asymptomatic or treated brain metastases were eligible. The study excluded patients with a history of chest radiation therapy; a history of active primary immunodeficiency; autoimmune disorders including paraneoplastic syndrome (PNS); active or prior documented autoimmune or inflammatory disorders; use of systemic immunosuppressants within 14 days before the first dose of the treatment except physiological dose of systemic corticosteroids; active tuberculosis or hepatitis B or C or HIV infection; or patients receiving live attenuated vaccine within 30 days before or after the start of IMFINZI.

Randomisation was stratified by the planned platinum-based (carboplatin or cisplatin) therapy in cycle 1.

Patients were randomised 1:1:1 to receive:

- Arm 1: IMFINZI 1 500 mg + tremelimumab 75 mg + etoposide and either carboplatin or cisplatin.
- Arm 2: IMFINZI 1 500 mg + etoposide and either carboplatin or cisplatin.
- Arm 3: Either carboplatin (AUC 5 or 6 mg/ml/min) or cisplatin (75-80 mg/m²) on Day 1 and etoposide (80-100 mg/m²) intravenously on Days 1, 2, and 3 of each 21-day cycle for between 4 – 6 cycles.

For patients randomised to Arm 1 and 2, etoposide and either carboplatin or cisplatin was limited to 4 cycles on an every 3-week schedule subsequent to randomisation. IMFINZI monotherapy continued every 4 weeks until disease progression or unacceptable toxicity. Administration of IMFINZI

monotherapy was permitted beyond disease progression if the patient was clinically stable and deriving clinical benefit as determined by the investigator.

Patients randomised to Arm 3 were permitted to receive a total of up to 6 cycles of etoposide and either carboplatin or cisplatin. After completion of etoposide + platinum, PCI was permitted only in Arm 3 per investigator discretion.

Tumour assessments were conducted at Week 6 and Week 12 from the date of randomisation, and then every 8 weeks until confirmed objective disease progression. Survival assessments were conducted every 2 months following treatment discontinuation.

The primary endpoints of the study were OS of IMFINZI + etoposide + platinum (Arm 2) vs. etoposide + platinum alone (Arm 3) and IMFINZI + tremelimumab + etoposide + platinum (Arm 1) vs. etoposide + platinum alone (Arm 3). The key secondary endpoint was PFS. Other secondary endpoints were ORR, OS and PFS landmarks and PRO. PFS and ORR were assessed using Investigator assessments according to RECIST v1.1.

The demographics and baseline disease characteristics were well balanced between the two study arms (268 patients in Arm 2 and 269 patients in Arm 3). Baseline demographics of the overall study population were as follows: male (69.6%), age $\geq$ 65 years (39.6%), median age 63 years (range: 28 to 82 years), white (83.8%), Asian (14.5%), Black or African American (0.9%), other (0.6 %), non-Hispanic or Latino (96.1%), current or past-smoker (93.1%), never smoker (6.9%), WHO/ECOG PS 0 (35.2%), WHO/ECOG PS 1 (64.8%), Stage IV 90.3%, 24.6% of the patients received cisplatin and 74.1% of the patients received carboplatin. In Arm 3, 56.8% of the patients received 6 cycles of etoposide + platinum and 7.8% of the patients received PCI.

At a planned interim (primary) analysis the study demonstrated a statistically significant improvement in OS with IMFINZI + etoposide + platinum (Arm 2) vs. etoposide + platinum alone (Arm 3) [HR=0.73 (95% CI: 0.591, 0.909), $p=0.0047$]. Although not formally tested for significance, IMFINZI + etoposide + platinum demonstrated an improvement in PFS vs. etoposide + platinum alone [HR=0.78 (95% CI: 0.645, 0.936)].

The PFS, ORR and DoR results from the planned final analysis (DCO: 27 Jan 2020) are summarized in Table 9. Kaplan-Meier curve for PFS is presented in Figure 14.

The OS results with the planned long-term OS follow-up analysis (DCO: 22 March 2021) (median follow-up: 39.3 months) are presented in Table 9. IMFINZI + etoposide + platinum (Arm 2) vs. etoposide + platinum (Arm 3) continued to demonstrate sustained improvement in OS. Kaplan-Meier curve for OS is presented in Figure 13.

Table 9. Efficacy Results for the CASPIAN Study

	Final analysis^a		Long-term follow-up analysis^b	
	Arm 2: IMFINZI + etoposide and either carboplatin or cisplatin (n=268)	Arm 3: etoposide + and either carboplatin or cisplatin (n=269)	Arm 2: IMFINZI + etoposide and either carboplatin or cisplatin (n=268)	Arm 3: etoposide + and either carboplatin or cisplatin (n=269)
OS				
Number of deaths (%)	210 (78.4)	231 (85.9)	221 (82.5)	248 (92.2)
Median OS (months) (95% CI)	12.9 (11.3, 14.7)	10.5 (9.3, 11.2)	12.9 (11.3, 14.7)	10.5 (9.3, 11.2)
HR (95% CI) ^{b,c}	0.75 (0.625, 0.910)		0.71 (0.595, 0.858)	
p-value ^d	0.0032		0.0003	

	Final analysis ^a		Long-term follow-up analysis ^b	
	Arm 2: IMFINZI + etoposide and either carboplatin or cisplatin (n=268)	Arm 3: etoposide + and either carboplatin or cisplatin (n=269)	Arm 2: IMFINZI + etoposide and either carboplatin or cisplatin (n=268)	Arm 3: etoposide + and either carboplatin or cisplatin (n=269)
OS at 18 months (%) (95% CI)	32.0 (26.5, 37.7)	24.8 (19.7, 30.1)	32.0 (26.5, 37.7)	24.8 (19.7, 30.1)
OS at 36 months (%) (95% CI)			17.6 (13.3, 22.4)	5.8 (3.4, 9.1)
PFS				
Number of events (%)	234 (87.3)	236 (87.7)		
Median PFS (months) (95% CI)	5.1 (4.7, 6.2)	5.4 (4.8, 6.2)		
HR (95% CI) ^c	0.80 (0.665, 0.959)			
PFS at 6 months (%) (95% CI)	45.4 (39.3, 51.3)	45.8 (39.5, 51.9)		
PFS at 12 months (%) (95% CI)	17.9 (13.5, 22.8)	5.3 (2.9, 8.8)		
ORR n (%) (95% CI)^e	182 (67.9) (62.0, 73.5)	156 (58.0) (51.8, 64.0)		
Complete Response n (%)	7 (2.6)	2 (0.7)		
Partial Response n (%)	175 (65.3)	154 (57.2)		
Median DoR (months) (95% CI)^{e,f}	5.1 (4.9, 5.3)	5.1 (4.8, 5.3)		

^a Final PFS, ORR and DoR analysis at data cut-off 27 January 2020.

^b Long-term follow-up OS analysis at data cut-off 22 March 2021.


^c The analysis was performed using the stratified log-rank test, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and using the rank tests of association approach.

^d At the interim analysis (data cut-off 11 March 2019) the OS p-value was 0.0047, which met the boundary for declaring statistical significance of 0.0178 for a 4% overall 2-sided alpha, based on a Lan-DeMets alpha spending function with O'Brien Fleming type boundary with the actual number of events observed.

^e Confirmed Objective Response.


^f Post-hoc analysis.

Figure 13. Kaplan-Meier curve of OS



Number of patients at risk	0	3	6	9	12	15	18	21	24	27	30	33	36	39	42	45	48	51
IMFINZI + etoposide + platinum	268	244	214	177	140	109	85	70	60	54	50	46	39	25	13	3	0	0
etoposide + platinum	269	243	212	156	104	82	64	51	36	24	19	17	13	10	3	0	0	0

Figure 14. Kaplan-Meier curve of PFS



Number of patients at risk	0	3	6	9	12	15	18	21	24	27	30	33
IMFINZI + etoposide + platinum	268	220	119	55	45	40	35	24	18	8	5	0
etoposide + platinum	269	195	110	33	12	9	7	7	6	1	0	0

Subgroup analysis

The improvements in OS in favour of patients receiving IMFINZI + etoposide + platinum compared to those receiving etoposide + platinum alone, were consistently observed across the prespecified subgroups based on demographics, geographical region, carboplatin or cisplatin use and disease characteristics.

BTC – TOPAZ-1 Study

TOPAZ-1 was a study designed to evaluate the efficacy of IMFINZI in combination with gemcitabine and cisplatin. TOPAZ-1 was a randomised, double-blind, placebo-controlled, multicentre study in 685 patients with unresectable or metastatic BTC (including intrahepatic and extrahepatic cholangiocarcinoma and gallbladder carcinoma) and ECOG Performance status of 0 or 1. Patients had not received previous therapy in the advanced/unresectable setting. Patients who developed recurrent disease > 6 months after surgery and/or completion of adjuvant therapy were included. Patients must have had an adequate organ and bone marrow function, and have had acceptable serum bilirubin levels ($\leq 2.0 \times$ the upper limit of normal (ULN)), and any clinically significant biliary obstruction had to be resolved before randomisation.

The study excluded patients with ampullary carcinoma, with brain metastases, active or prior documented autoimmune or inflammatory disorders, HIV infection or active infections, including tuberculosis or hepatitis C or patients with current or prior use of immunosuppressive medication within 14 days before the first dose of IMFINZI. Patients with active HBV were allowed to participate if they were on antiviral therapy.

Randomisation was stratified by disease status (initially unresectable vs. recurrent) and primary tumour location (intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder carcinoma).

Patients were randomised 1:1 to receive:

- Arm 1: IMFINZI 1 500 mg administered on Day 1 + gemcitabine 1 000 mg/m² and cisplatin 25 mg/m² (each administered on Days 1 and 8) every 3 weeks (21 days) for up to 8 cycles, followed by IMFINZI 1 500 mg every 4 weeks until disease progression or unacceptable toxicity, or
- Arm 2: Placebo administered on Day 1 + gemcitabine 1 000 mg/m² and cisplatin 25 mg/m² (each administered on Days 1 and 8) every 3 weeks (21 days) for up to 8 cycles, followed by placebo every 4 weeks until disease progression or unacceptable toxicity.

Tumour assessments were conducted every 6 weeks for the first 24 weeks after the date of randomisation, and then every 8 weeks until confirmed objective disease progression.

The primary endpoint of the study was OS, the key secondary endpoint was PFS. Other secondary endpoints were ORR, DoR and PRO. PFS, ORR and DoR were investigator-assessed according to RECIST v1.1.

The demographics and baseline disease characteristics were well balanced between the two study arms (341 patients in Arm 1 and 344 patients in Arm 2). Baseline demographics of the overall study population were as follows: male (50.4%), age < 65 years (53.3%), white (37.2%), Asian (56.4%), Black or African American (2.0%), other (4.2%), non-Hispanic or Latino (93.1%), ECOG PS 0 (49.1%), vs. PS 1 (50.9%), primary tumour location (intrahepatic bile duct 55.9%, extrahepatic bile duct 19.1% and gallbladder 25.0%), disease status [recurrent (19.1%) vs. unresectable (80.7%), metastatic (86.0%) vs. locally advanced (13.9%)]. PD-L1 expression was evaluated on tumour and immune cells using the Ventana PD-L1 (SP263) assay and the TAP (tumour area positivity) algorithm, 58.7% patients had TAP ≥ 1% and 30.1% TAP < 1%.

OS and PFS were formally tested at a pre-planned interim analysis (data cut-off 11 Aug 2021) after a median follow-up of 9.8 months. Efficacy results are shown in Table 10 and Figure 16. The maturity for OS was 62% and the maturity for PFS was 84%. IMFINZI + chemotherapy (Arm 1) showed statistically significant improvement vs. placebo + chemotherapy (Arm 2) in OS and in PFS.

Table 10. Efficacy Results for the TOPAZ-1 Study^a

	IMFINZI + gemcitabine and cisplatin (n=341)	Placebo + gemcitabine and cisplatin (n=344)
OS		
Number of deaths (%)	198 (58.1)	226 (65.7)
Median OS (months) (95% CI)^b	12.8 (11.1, 14.0)	11.5 (10.1, 12.5)
HR (95% CI) ^c	0.80 (0.66, 0.97)	
p-value ^{c,d}	0.021	
Median follow-up in all patients (months)	10.2	9.5
PFS		
Number of events (%)	276 (80.9)	297 (86.3)
Median PFS (months) (95% CI)^b	7.2 (6.7, 7.4)	5.7 (5.6, 6.7)
HR (95% CI) ^c	0.75 (0.63, 0.89)	
p-value ^{c,e}	0.001	
Median follow-up in all patients (months)	7.2	5.6
ORR^f	91 (26.7)	64 (18.7)
Complete Response n (%)	7 (2.1)	2 (0.6)
Partial Response n (%)	84 (24.6)	62 (18.1)
DoR		
Median DoR (months) (95% CI)^b	6.4 (5.9, 8.1)	6.2 (4.4, 7.3)

^a Analysis at data cut-off 11 August 2021.

^b Calculated using the Kaplan-Meier technique. CI for median derived based on Brookmeyer-Crowley method.

^c The analysis for HR was performed using a stratified Cox proportional hazards model and 2-sided p-value is based on a stratified log-rank test, both are adjusted for disease status and primary tumour location.

^d At the interim analysis (data cut-off 11 August 2021) the OS p-value was 0.021, which met the boundary for declaring statistical significance of 0.03 for a 4.9% overall 2-sided alpha, based on a Lan-DeMets alpha spending function with O'Brien Fleming type boundary with the actual number of events observed.

^e At the interim analysis (data cut-off 11 August 2021) the PFS p-value was 0.001, which met the boundary for declaring statistical significance of 0.0481 for a 4.9% overall 2-sided alpha, based on a Lan-DeMets alpha spending function with Pocock-type boundary with the actual number of events observed.

^f Confirmed objective response.

An additional planned follow-up analysis of OS (data cut-off 25 Feb 2022) was performed 6.5 months after the interim analysis with an OS maturity of 77%. IMFINZI + chemotherapy continued to demonstrate improved OS vs. chemotherapy alone [HR=0.76, (95% CI: 0.64, 0.91)] and the median follow-up increased to 12 months.

Figure 15: Kaplan-Meier curve of OS, follow-up OS analysis at data cut-off 25 February 2022





Figure 16: Kaplan-Meier curve of PFS, inferential (primary) analysis at data cut-off 11 August 2021



HCC - HIMALAYA Study

The efficacy of IMFINZI as monotherapy and given in combination with a single dose of tremelimumab 300 mg was evaluated in the HIMALAYA Study, a randomised, open-label, multicentre study in patients with confirmed uHCC who did not receive prior systemic treatment for HCC. The study included patients with Barcelona Clinic Liver Cancer (BCLC) Stage C or B (not eligible for locoregional therapy) and Child-Pugh Score Class A.

The study excluded patients with brain metastases or a history of brain metastases, co-infection of viral hepatitis B and hepatitis C; active or prior documented gastrointestinal (GI) bleeding within 12 months; ascites requiring non-pharmacologic intervention within 6 months; hepatic encephalopathy within 12 months before the start of treatment; active or prior documented autoimmune or inflammatory disorders.

Patients with oesophageal varices were included except those with active or prior documented GI bleeding within 12 months prior to study entry.

Randomisation was stratified by macrovascular invasion (MVI) (yes vs. no), aetiology of liver disease (confirmed hepatitis B virus vs. confirmed hepatitis C virus vs. others) and ECOG performance status (0 vs. 1). The HIMALAYA study randomised 1 171 patients 1:1:1 to receive:

- IMFINZI: durvalumab 1 500 mg every 4 weeks.
- Tremelimumab 300 mg as a single dose + IMFINZI 1 500 mg; followed by IMFINZI 1 500 mg every 4 weeks.
- Sorafenib 400 mg twice daily.

Tumour assessments were conducted every 8 weeks for the first 12 months and then every 12 weeks thereafter. Survival assessments were conducted every month for the first 3 months following treatment discontinuation and then every 2 months.

The primary endpoint was OS superiority for the comparison of IMFINZI given in combination with a single dose of tremelimumab vs. Sorafenib. The key secondary objectives were OS non-inferiority followed by superiority for the comparison of IMFINZI vs. Sorafenib. Other secondary endpoints included PFS, Investigator-assessed ORR and DoR according to RECIST v1.1.

The demographics and baseline disease characteristics were well balanced among study arms. The baseline demographics of the overall study population were as follows: male (83.7%), age < 65 years (50.4%) White (44.6%), Asian (50.7%), Black or African American (1.7%), Other race (2.3%), ECOG PS 0 (62.6%); Child-Pugh Class score A (99.5%), macrovascular invasion (25.2%), extrahepatic spread (53.4%), baseline AFP < 400 ng/ml (63.7%), baseline AFP ≥ 400 ng/ml (34.5%), viral aetiology; hepatitis B (30.6%), hepatitis C (27.2%), uninfected (42.2%), evaluable PD-L1 data (86.3%), PD-L1 Tumour area positivity (TAP) ≥ 1% (38.9%), PD-L1 TAP < 1% (48.3%) [Ventana PD-L1 (SP263) assay].

Results are presented in Table 11, Figure 17 and Figure 18.

Table 11. Efficacy Results for the HIMALAYA Study for IMFINZI given in combination with a single dose of tremelimumab 300 mg and IMFINZI as monotherapy vs. Sorafenib

	IMFINZI + tremelimumab 300 mg (n=393)	Sorafenib (n=389)	IMFINZI (n=389)
Follow-up duration			
Median follow up (months) ^a	33.2	32.2	32.6
OS			
Number of deaths (%)	262 (66.7)	293 (75.3)	280 (72.0)

	IMFINZI + tremelimumab 300 mg (n=393)	Sorafenib (n=389)	IMFINZI (n=389)
Median OS (months) (95% CI)	16.4 (14.2, 19.6)	13.8 (12.3, 16.1)	16.6 (14.1, 19.1)
HR (95% CI) ^{b,c}	0.78 (0.66, 0.92)		-
p-value ^d	0.0035		-
HR (95% CI) ^{b,c,e}	-	0.86 (0.73, 1.03)	
PFS			
Number of events (%)	335 (85.2)	327 (84.1)	345 (88.7)
Median PFS (months) (95% CI)	3.78 (3.68-5.32)	4.07 (3.75-5.49)	3.65 (3.19-3.75)
HR (95% CI)	0.90 (0.77, 1.05)		-
HR (95% CI)	-	1.02 (0.88, 1.19)	
ORR			
ORR n (%) ^f	79 (20.1)	20 (5.1)	66 (17.0)
Complete Response n (%)	12 (3.1)	0	6 (1.5)
Partial Response n (%)	67 (17.0)	20 (5.1)	60 (15.4)
DoR			
Median DoR (months)	22.3	18.4	16.8

^a Calculated using reverse the Kaplan-Meier technique (with censor indicator reversed).

^b Based on stratified Cox-model adjusting for treatment, etiology of liver disease (HBV vs. HCV vs. others), ECOG (0 vs. 1).

^c Performed using stratified log-rank test adjusting for treatment, etiology of liver disease (HBV vs. HCV vs. others), ECOG (0 vs. 1), and macro-vascular invasion (yes vs. no).

^d Based on a Lan-DeMets alpha spending function with O'Brien Fleming type boundary and the actual number of events observed, the boundary for declaring statistical significance for IMFINZI + tremelimumab 300 mg vs. Sorafenib was 0.0398 (Lan and DeMets 1983).

^e Non-inferiority margin for HR (IMFINZI vs. Sorafenib) is 1.08 using a 95.67% confidence interval based on a Lan-DeMets alpha spending function with O'Brien Fleming type boundary and the actual number of events observed (Lan and DeMets 1983). P-value based on superiority testing of IMFINZI vs. Sorafenib was 0.0674 and did not reach statistical significance.

^f Confirmed complete response.

CI=Confidence Interval

Figure 17. Kaplan-Meier curve of OS of IMFINZI given in combination with a single dose of tremelimumab 300 mg





Figure 18. Kaplan-Meier curve of OS of IMFINZI given as monotherapy



Endometrial Cancer – DUO-E Study

DUO-E was a randomised, multicentre, double-blind, placebo-controlled Phase III study of first-line platinum-based chemotherapy in combination with IMFINZI, followed by IMFINZI with or without olaparib in patients with advanced or recurrent endometrial cancer. Patients had to have endometrial cancer in one of the following categories: newly diagnosed Stage III disease (measurable disease per RECIST v1.1 following surgery or diagnostic biopsy), newly diagnosed Stage IV disease (with or without disease following surgery or diagnostic biopsy), or recurrence of disease (measurable or non-measurable disease per RECIST v1.1) where the potential for cure by surgery alone or in combination is poor. For patients with recurrent disease, prior chemotherapy was allowed only if it was administered in the adjuvant setting and there was at least 12 months from the date of last dose of chemotherapy administered to the date of subsequent relapse. The study included patients with epithelial endometrial carcinomas of all histologies, including carcinosarcomas. Patients with endometrial sarcoma were excluded.

Randomisation was stratified by tumour tissue's mismatch repair (MMR) status (proficient versus deficient), disease status (recurrent versus newly diagnosed), and geographic region (Asia versus rest of the world). Patients were randomised 1:1:1 to one of the following arms:

- Arm 1 (Platinum-based chemotherapy): Platinum-based chemotherapy (paclitaxel and carboplatin) every 3 weeks for a maximum of 6 cycles with durvalumab placebo every 3 weeks. Following completion of chemotherapy treatment, patients without objective disease progression received durvalumab placebo every 4 weeks and olaparib placebo tablets twice daily as maintenance treatment until disease progression.
- Arm 2 (Platinum-based chemotherapy + IMFINZI): Platinum-based chemotherapy (paclitaxel and carboplatin) every 3 weeks for a maximum of 6 cycles with 1 120 mg durvalumab every 3 weeks. Following completion of chemotherapy treatment, patients without objective disease progression received 1 500 mg durvalumab every 4 weeks with olaparib placebo tablets twice daily as maintenance treatment until disease progression.
- Arm 3 (Platinum-based chemotherapy + IMFINZI + olaparib): Platinum-based chemotherapy (paclitaxel and carboplatin) every 3 weeks for a maximum of 6 cycles with 1 120 mg durvalumab every 3 weeks. Following completion of chemotherapy treatment, patients without objective disease progression received 1 500 mg durvalumab every 4 weeks with 300 mg olaparib tablets twice daily as maintenance treatment until disease progression.

Patients who discontinued either product (IMFINZI/placebo or olaparib/placebo) for reasons other than disease progression could continue treatment with the other product if appropriate based on toxicity considerations and investigator discretion.

Treatment was continued until RECIST v1.1-defined progression of disease or unacceptable toxicity. Assessment of tumour status was performed every 9 weeks for the first 18 weeks relative to randomisation and every 12 weeks thereafter.

The primary endpoint was PFS, determined by investigator assessment using RECIST v1.1. Secondary efficacy endpoints included OS, ORR and DoR.

The study demonstrated a statistically significant improvement in PFS in the ITT population, for patients treated with platinum-based chemotherapy + IMFINZI + olaparib compared to platinum-based chemotherapy [HR=0.55 (95% CI: 0.43, 0.69), $p < 0.0001$], and for patients treated with platinum-based chemotherapy + IMFINZI compared to platinum-based chemotherapy [HR=0.71 (95% CI: 0.57, 0.89), $p = 0.003$]. At the time of PFS analysis, interim OS data were 28% mature with events in 199 of 718 patients.

Mismatch repair (MMR) status was determined centrally using an MMR immunohistochemistry panel assay. Of a total of 718 patients randomised in the study, 575 (80%) patients had MMR-proficient (pMMR) tumour status and 143 (20%) patients had MMR-deficient (dMMR) tumour status.

Patients with MMR-deficient (dMMR) endometrial cancer

Among patients with dMMR tumour status, demographic and baseline characteristics were generally well balanced between the treatment arms. Baseline demographics across all three arms were as follows: median age of 62 years (range: 34 to 85), 41% age 65 or older, 1.5% age 75 or older, 62% White, 29% Asian, and 2% Black or African American. Disease characteristics were as follows: ECOG PS of 0 (58%) or 1 (42%), 46% newly diagnosed and 54% recurrent disease. The histologic subtypes were endometrioid (83%), mixed epithelial (5%), serous (3%), carcinosarcoma (3%), undifferentiated (2%), and other (3%).

In patients with dMMR tumour status, the results are summarised in Table 12 and Figure 19. The median follow-up time for PFS in censored patients with dMMR tumour status was 15.5 months in the platinum-based chemotherapy + IMFINZI arm and 10.2 months in the platinum-based chemotherapy arm. At the time of PFS analysis, interim OS data were 26% mature with events in 25 of 95 patients treated with platinum-based chemotherapy + IMFINZI and platinum-based chemotherapy.

Table 12. Efficacy results for the DUO-E Study (Patients with dMMR tumour status)

	Platinum-based chemotherapy + IMFINZI N=46	Platinum-based chemotherapy N=49
PFS^{a,b}		
Number of events (%)	15 (32.6)	25 (51.0)
Median PFS (months) (95% CI)^c	NR (NR, NR)	7.0 (6.7, 14.8)
HR (95% CI)	0.42 (0.22, 0.80)	-
OS^b		
Number of events (%)	7 (15.2)	18 (36.7)
Median OS (months) (95% CI)^c	NR (NR, NR)	23.7 (16.9, NR)
HR (95% CI)	0.34 (0.13, 0.79)	-
ORR^b		
ORR ^d n (%)	30 (71.4)	17 (40.5)
DoR^b		
Median DoR (months) (95% CI)^c	NR (NR, NR)	10.5 (4.3, NR)


^a Investigator assessed.

^b Results are based on the first interim analysis (DCO: 12 April 2023).

^c Calculated using the Kaplan-Meier technique.

^d Response: Best objective response as confirmed complete response or partial response. Based on number of patients in treatment group with measurable disease at baseline (N=42 in platinum-based chemotherapy + IMFINZI arm, N=42 in platinum-based chemotherapy arm).

CI=Confidence Interval, HR=Hazard Ratio, NR=Not Reached

Figure 19. Kaplan-Meier curve of PFS in DUO-E (Patients with dMMR tumour status)

Number of patients at risk:

Platinum-based chemotherapy + IMFINZI	46	37	36	31	26	19	14	9	5	2	0
Platinum-based chemotherapy	49	41	28	17	13	8	5	2	2	0	0

Patients with MMR-proficient (pMMR) endometrial cancer

Among patients with pMMR tumour status, demographic and baseline characteristics were generally well balanced between the treatment arms. Baseline demographics across all three arms were as follows: median age of 64 years (range: 22 to 86), 48% age 65 or older, 8.1% age 75 or older, 56% White, 30% Asian, and 6% Black or African American. Disease characteristics were as follows: ECOG PS of 0 (69%) or 1 (31%), 47% newly diagnosed and 53% recurrent disease. The histologic subtypes were endometrioid (54%), serous (26%), carcinosarcoma (8%), mixed epithelial (4%), clear cell (3%), undifferentiated (2%), mucinous (< 1%), and other (3%).

Results in patients with pMMR tumour status are summarised in Table 13 and Figure 20. The median follow-up time in censored patients with pMMR tumour status was 15.2 months in the platinum-based chemotherapy + IMFINZI + olaparib arm, and 12.8 months in the platinum-based chemotherapy arm.

At the time of PFS analysis, interim OS data were 29% mature with events in 110 of 383 patients treated with platinum-based chemotherapy + IMFINZI + olaparib and platinum-based chemotherapy.

Table 13. Efficacy results for the DUO-E Study (Patients with pMMR tumour status)

	Platinum-based chemotherapy + IMFINZI + olaparib N=191	Platinum-based chemotherapy N=192
PFS^{a,b}		
Number of events (%)	108 (56.5)	148 (77.1)
Median PFS (months) (95% CI)^c	15.0 (12.4, 18.0)	9.7 (9.2, 10.1)
HR (95% CI)	0.57 (0.44, 0.73)	-
OS^b		
Number of events (%)	46 (24.1)	64 (33.3)
Median OS (months) (95% CI)^c	NR (NR, NR)	25.9 (25.1, NR)
HR (95% CI)	0.69 (0.47, 1.00)	-
ORR^b		
ORR ^d n (%)	90 (61.2)	92 (59.0)
DoR^b		
Median DoR (months) (95% CI)^c	18.7 (10.5, NR)	7.6 (7.1, 10.2)

^a Investigator assessed.


^b Results are based on the first interim analysis (DCO: 12 April 2023).

^c Calculated using the Kaplan-Meier technique.

^d Response: Best objective response as confirmed complete response or partial response. Based on number of patients in treatment group with measurable disease at baseline (N=147 in platinum-based chemotherapy + IMFINZI + olaparib arm, N=156 in platinum-based chemotherapy arm).

CI=Confidence Interval, HR=Hazard Ratio, NR=Not Reached

Figure 20. Kaplan-Meier curve of PFS in DUO-E (Patients with pMMR tumour status)



Among patients with pMMR tumour status, the PFS HRs were 0.44 (95% CI: 0.31, 0.61) in patients with PD-L1 expression positive status (236/383; 62%) and 0.87 (95% CI: 0.59, 1.28) in patients with PD-L1 expression negative status (140/383; 37%), for the platinum-based chemotherapy + IMFINZI + olaparib arm compared to the platinum-based chemotherapy arm. PD-L1 expression positive was defined as tumour area positive (TAP) $\geq 1\%$.

Muscle invasive bladder cancer (MIBC) – NIAGARA Study

NIAGARA was a randomised, open-label, multicentre Phase III study designed to evaluate the efficacy of neoadjuvant IMFINZI in combination with gemcitabine and cisplatin followed by adjuvant IMFINZI monotherapy in patients with MIBC. The study randomised 1 063 patients who were candidates for radical cystectomy and had not received prior systemic chemotherapy or immune-mediated therapy for the treatment of MIBC with clinical tumour stage T2-T4aN0/1M0. The study excluded patients with pure non-urothelial histology, any small cell histology and primary non-bladder (i.e. ureter, urethral, or renal pelvis) cancer of the urothelium, active or prior documented autoimmune disease, active tuberculosis or hepatitis B or C or HIV infection, or use of immuno-suppressive medication within 14 days of the first dose of durvalumab except systemic corticosteroids when used at physiological doses or as premedication.

Randomisation was stratified by clinical tumour stage T2N0 vs. > T2N0 (including T2N1, T3, and T4a), renal function (adequate renal function: creatinine clearance [CrCl] ≥ 60 mL/min vs. borderline renal function: CrCl ≥ 40 mL/min to < 60 mL/min), and PD-L1 expression (high vs. low/negative) status. Patients were randomised 1:1 to receive perioperative IMFINZI with neoadjuvant chemotherapy (Arm 1) or neoadjuvant chemotherapy alone (Arm 2):

- Arm 1 (IMFINZI + chemotherapy): IMFINZI 1 500 mg + gemcitabine 1 000 mg/m² and cisplatin 70 mg/m² every 3 weeks for 4 cycles prior to surgery, followed by IMFINZI 1 500 mg every 4 weeks for up to 8 cycles after surgery, or
- Arm 2 (Chemotherapy): Gemcitabine 1 000 mg/m² and cisplatin 70 mg/m² every 3 weeks for 4 cycles prior to surgery, without post-surgery treatment.

Patients with borderline renal function received split dose cisplatin of 35 mg/m² on days 1 and 8 of each cycle.

A RECIST 1.1 tumour assessment was performed at baseline and upon completion of neoadjuvant therapy (prior to surgery). After surgery, RECIST 1.1 tumour assessments were performed every 12 weeks for the first 24 months, then every 24 weeks for 36 months, and then every 52 weeks thereafter until progression, the end of study, or death.

The primary endpoints were pathological complete response (pCR) by blinded central pathology review and event-free survival (EFS) which included blinded independent central review (BICR) assessment. Overall survival (OS) was a key secondary endpoint.

The demographics and baseline disease characteristics were generally well-balanced between the 533 patients in Arm 1 and 530 patients in Arm 2. Baseline demographics were as follows: male (81.8%), age <65 years (46.9%), white (67%), Asian (27.9%), black or African American (0.9%), other (0.8%), Hispanic or Latino (8.0%), and ECOG PS 0 (78%) vs. PS 1 (22%). Disease characteristics were as follows: Tumour Stage T2N0 (40.3%) and > T2N0a (59.7%), regional lymph nodes N0 (94.5%) and N1 (5.5%), adequate renal function (81.1%) and borderline renal function (18.9%), and PD-L1 expression status high (73.1%) and low/negative (26.9%). The histologic subtypes included urothelial carcinoma (84.5%), urothelial carcinoma with squamous differentiation (8.2%), urothelial carcinoma with variant histology (5.0%), and urothelial carcinoma with glandular differentiation (2.4%).

In the overall population, 469 (88.0%) patients in Arm 1 and 441 (83.2%) patients in Arm 2 underwent radical cystectomy.

Results are presented in Table 14, Figure 21 and Figure 22.

Table 14: Efficacy Results for the NIAGARA Study


	IMFINZI + chemotherapy (N=533)	Chemotherapy (N=530)
EFS^a		
Number of events (%)	187 (35.1)	246 (46.4)
Median EFS (months) (95% CI)^b	NR (NR, NR)	46.1 (32.2, NR)
HR (95% CI) ^c	0.68 (0.56, 0.82)	
2-sided p-value ^{d,e}	< 0.0001	
pCR^f		
Number of patients with response	180	137
Response rate, % (95% CI) ^g	33.8 (29.8, 38.0)	25.8 (22.2, 29.8)
Odds ratio (95% CI) ^h	1.49 (1.14, 1.96)	
2-sided p-value ^h	0.0038	
OS^a		
Number of events (%)	136 (25.5)	169 (31.9)
Median OS (months) (95% CI)^b	NR (NR, NR)	NR (NR, NR)
HR (95% CI) ^c	0.75 (0.59, 0.93)	
2-sided p-value ^{d,e}	0.0106	

^a Results are based on a pre-planned interim analysis (DCO: 29 April 2024) which occurred 68 months after study initiation.

^b Calculated using the Kaplan-Meier technique.

- ^c Based on stratified Cox proportional hazard model with tumour stage [T2N0 vs. > T2N0], renal function [adequate vs. borderline], and PD-L1 status [high vs. low/negative] as stratification factors.
 - ^d Based on stratified log-rank test with tumour stage [T2N0 vs. > T2N0], renal function [adequate vs borderline], and PD-L1 status [high vs low/negative] as stratification factors.
 - ^e The boundary for declaring statistical significance for the primary efficacy endpoints pCR rate, EFS and the key secondary endpoint OS were determined by a multiple test procedure with an alpha-exhaustive recycling strategy. Alpha allocated to EFS and OS at the interim analysis was based on a Lan-DeMets alpha spending function with O'Brien Fleming approach (pCR = 0.001, EFS = 0.0412, OS = 0.0154, 2-sided).
 - ^f Based on the final analysis of pCR (DCO: 14 Jan 2022).
 - ^g CI was calculated using the Clopper Pearson method.
 - ^h Obtained using logistic regression adjusted for the stratification factors (renal function [adequate vs. borderline], tumour stage [T2N0 vs. > T2N0] and PD-L1 status [high vs. low/negative] per IVRS).
- CI=Confidence Interval, HR=Hazard Ratio, NR=Not Reached


Figure 21. Kaplan-Meier Curve of EFS



Number of patients at risk:

IMFINZI+Chemotherapy	533	519	475	454	424	401	386	370	356	348	344	335	330	321	315	312	282	269	255	214	202	180	141	140	115	86	81	32	20	20	1	0
Chemotherapy	530	498	437	416	381	358	343	328	313	300	296	288	281	273	264	259	228	219	214	177	172	159	132	129	94	69	62	24	18	16	2	0

Figure 22. Kaplan-Meier Curve of OS



Number of patients at risk:

IMFINZI+Chemotherapy	533	528	517	505	492	478	468	457	446	440	434	428	423	418	410	408	400	375	349	321	295	271	238	207	182	152	125	96	68	34	21	7	1	0
Chemotherapy	530	516	507	490	467	450	438	425	413	402	392	383	378	373	368	363	358	334	311	281	259	239	215	194	174	141	113	90	60	38	21	10	2	0

Subgroup analysis

In an exploratory analysis by tumour stage, the EFS HR was 0.61 (95% CI: 0.48, 0.78) in the subgroup of patients with clinical stage > T2N0 (N=635) and 0.81 (95% CI: 0.60, 1.10) in the subgroup of patients with clinical stage T2N0 (N=428). The OS HR was 0.67 (95% CI: 0.50, 0.89) in the subgroup

of patients with clinical stage $\geq$ T2N0 and 0.89 (95% CI: 0.62, 1.29) in patients with clinical stage T2N0.

Resectable GC/GEJC – MATTERHORN Study

MATTERHORN was a randomised, double-blind, placebo-controlled, multicentre, Phase III study to evaluate the efficacy of IMFINZI in combination with FLOT (5-FU, leucovorin, oxaliplatin, docetaxel) chemotherapy as neoadjuvant and adjuvant treatment, followed by adjuvant IMFINZI monotherapy, in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (Stage IIA to Stage IVA [AJCC, 8th edition]). The study enrolled previously untreated patients with documented GC/GEJC, with no prior exposure to immune-mediated therapy, and WHO/ECOG performance status of 0 or 1. Patients were enrolled regardless of PD-L1 expression level. Prior to randomisation, patients had tumour PD-L1 expression level confirmed using the TAP scoring method, which is defined as the total percentage of the tumour area (tumour and any desmoplastic stroma) covered by tumour cells with PD-L1 membrane staining at any intensity and tumour-associated immune cells with PD-L1 staining at any intensity as visually estimated, by the Ventana PD-L1 (SP263) Assay. The study excluded patients with active or prior documented autoimmune or inflammatory disorders, or use of immunosuppressive medication within 14 days of the first dose of durvalumab.

Randomisation was stratified by geographic region (Asia vs. non-Asia), clinical lymph node status (positive vs. negative), and PD-L1 expression level (TAP $< 1\%$ vs. TAP $\geq 1\%$).

Patients were randomised in a 1:1 ratio to one of the following treatment arms. Crossover between the study arms was not permitted.

- Arm 1: IMFINZI 1 500 mg on Day 1 + FLOT (5-FU 2 600 mg/m², Leucovorin 200 mg/m², Oxaliplatin 85 mg/m², Docetaxel 50 mg/m²) chemotherapy on Days 1 and 15 every 4 weeks for 4 cycles (1 dose of IMFINZI and 2 doses of FLOT per cycle; 2 cycles in the neoadjuvant phase + 2 cycles in the adjuvant phase) followed by IMFINZI 1 500 mg on Day 1 every 4 weeks for up to 10 additional cycles post-surgery for a total of 12 cycles (1 dose per cycle)
- Arm 2: Placebo on Day 1 + FLOT (5-FU 2 600 mg/m², Leucovorin 200 mg/m², Oxaliplatin 85 mg/m², Docetaxel 50 mg/m²) chemotherapy on Days 1 and 15 every 4 weeks for 4 cycles (1 dose of placebo and 2 doses of FLOT per cycle; 2 cycles in the neoadjuvant phase + 2 cycles in the adjuvant phase) followed by placebo on Day 1 every 4 weeks for up to 10 additional cycles post-surgery for a total of 12 cycles (1 dose per cycle)

Patients in either the neoadjuvant or adjuvant phase who discontinued FLOT chemotherapy due to reasons other than disease progression or recurrence could, based on investigator discretion, continue treatment with IMFINZI monotherapy as described above.

A baseline RECIST 1.1 tumour assessment was performed prior to the start of neoadjuvant therapy, with a follow-up scan prior to surgery within 4 weeks after the final chemotherapy dose. An adjuvant baseline scan was performed no sooner than 4 weeks after surgery and before starting the adjuvant treatment. Tumour assessments were conducted every 12 weeks (relative to the adjuvant baseline scan) for 2 years, then every 24 weeks until RECIST 1.1 defined radiological progression, consent withdrawal, or death.

The primary endpoint of the study was EFS by BICR assessment, defined as the time from randomisation until the date of one of the following events (whichever occurred first): disease progression according to RECIST, version 1.1, as assessed by blinded independent central review (BICR), that precluded surgery or that required non-protocol therapy during the neoadjuvant treatment period; progression or recurrence according to RECIST, version 1.1, during the adjuvant treatment period; non-RECIST progression (according to investigator assessment or confirmed by biopsy) that precluded surgery or that required non-protocol therapy during the neoadjuvant treatment period or that was discovered during surgery; progression or recurrence confirmed by biopsy after surgery; or

death from any cause. The key secondary endpoints were OS and pCR rate by blinded central pathology review.

The demographics and baseline disease characteristics were generally well balanced between the two study arms (474 patients in Arm 1 and 474 patients in Arm 2). The baseline demographics of the population were as follows: male (71.9%), age ≥ 65 years (41.4%), median age 62 years (range: 26 to 84), White (67.8%), Asian (20.4%), Black or African American (1.1%), American Indian or Alaska Native (4.0%), Other Race (1.7%), Not Hispanic or Latino (80.0%), WHO/ECOG PS 0 (74.2%) versus PS 1 (25.8%). Disease characteristics were as follows: Stage II (29.4%), Stage III (61.7%), Stage IVA (8.8%), Gastric (67.5%), Gastro-oesophageal junction (32.5%), Siewert type 1 (10.4%), Siewert type 2 (14.8%), Siewert type 3 (7.3%), Intestinal type (50.9%), Diffuse type (26.3%), Indeterminate type (22.8%), Clinical lymph node status Positive (70.4%), Clinical lymph node status Negative (29.2%), PD-L1 expression status TAP $\geq 1\%$ (90.0%), PD-L1 expression status TAP $< 1\%$ (10.0%).

There were 431 (90.9%) patients in Arm 1 who attempted curative intent surgery compared to 428 (90.3%) patients in Arm 2. There were 412 (86.9%) patients in Arm 1 who completed curative intent surgery compared to 400 (84.4%) patients in Arm 2.

Table 15: Efficacy Results for the MATTERHORN Study

	IMFINZI + FLOT chemotherapy (N=474)	Placebo + FLOT chemotherapy (N=474)
EFS^a		
Number of events, n (%)	167 (35.2%)	218 (46%)
Median EFS (months) (95% CI) ^b	NR (40.7, NR)	32.8 (27.9, NR)
HR (95% CI) ^c	0.71 (0.58, 0.86)	
2-sided p-value ^{d,e}	< 0.001	
EFS at 24 months, % (95% CI) ^b	67.4 (62.9, 71.6)	58.5 (53.8, 63.0)
OS^f		
Number of deaths (%)	160 (33.8%)	192 (40.5%)
Median OS (95% CI) (months) ^b	NR (NR, NR)	NR (NR, NR)
HR (95% CI) ^c	0.78 (0.63, 0.96)	
2-sided p-value ^{d,g}	0.021	
OS at 24 months, % (95% CI) ^b	75.5 (71.4, 79.1)	70.4 (66.0, 74.3)
OS at 36 months, % (95% CI) ^b	68.6 (64.2, 72.6)	61.9 (57.3, 66.2)

^a Results are based on an EFS pre-specified interim analysis (DCO: 20 December 2024).

^b Calculated using the Kaplan-Meier technique.

^c Based on stratified Cox proportional hazards model stratified by geographical region, clinical lymph node status and PD-L1 expression status at randomisation. An HR < 1 favours IMFINZI. CI calculated using the profile likelihood approach.

^d Based on stratified log-rank test adjusting for geographic region, clinical lymph node status, and PD-L1 expression status at randomisation.


^e Based on a Lan-DeMets alpha spending function with O'Brien Fleming boundary calculated using the actual number of events at the DCO, the boundary for declaring statistical significance of EFS was 0.0239 for an overall alpha of 5% (2-sided).

^f Results are based on an OS pre-specified final analysis (DCO: 01 September 2025).

^g An alpha of 4.99% (2-sided) was allocated to the final analysis of OS, corresponding to a boundary for declaring statistical significance of 0.0499.

CI=Confidence Interval, HR=Hazard Ratio, NR=Not reached


Figure 23: Kaplan-Meier Curve of EFS



Number of patients at risk

IMFINZI+FLOT Chemotherapy	474	436	404	381	351	334	320	307	288	234	187	107	88	33	20	2	1	0	474/167
FLOT Chemotherapy	474	429	392	360	329	302	278	264	249	202	160	89	65	26	21	2	1	0	474/218

Figure 24: Kaplan-Meier Curve of OS



Number of patients at risk

IMFINZI+FLOT chemotherapy	474	464	438	422	403	389	377	367	351	338	334	323	316	255	182	112	71	29	6	1	0	474/160
FLOT chemotherapy	474	457	439	414	395	374	355	338	324	310	298	293	278	221	167	99	61	23	7	0	0	474/192

Subgroup analysis

In a predefined exploratory analysis by clinical lymph node status, the EFS HR was 0.67 (95% CI: 0.53, 0.84) in the clinical lymph node positive subgroup (N=667) and 0.85 (95% CI: 0.57, 1.27) in the clinical lymph node negative subgroup (N=277). The OS HR was 0.73 (95% CI: 0.57, 0.94) in the clinical lymph node positive subgroup and 1.01 (95% CI: 0.67, 1.51) in the clinical lymph node negative subgroup.

Paediatric population

The safety and efficacy of IMFINZI in combination with tremelimumab in children and adolescents aged less than 18 years has not been established. Study D419EC00001 was a multi-centre, open-label dose finding and dose expansion study to evaluate the safety, preliminary efficacy and pharmacokinetics of IMFINZI in combination with tremelimumab followed by IMFINZI monotherapy, in paediatric patients with advanced malignant solid tumours (except primary central

nervous system tumours) who had disease progression and for whom no standard of care treatment exists. The study enrolled 50 paediatric patients with an age range from 1 to 17 years with primary tumour categories: neuroblastoma, solid tumour and sarcoma. Patients received either IMFINZI 20 mg/kg in combination with tremelimumab 1 mg/kg or IMFINZI 30 mg/kg in combination with tremelimumab 1 mg/kg intravenously every 4 weeks for 4 cycles, followed by IMFINZI as monotherapy every 4 weeks. In the dose finding phase, IMFINZI and tremelimumab combination therapy was preceded by a single cycle of IMFINZI monotherapy; 8 patients in this phase however discontinued treatment prior to receiving tremelimumab. Thus, of the 50 patients enrolled in the study, 42 received IMFINZI in combination with tremelimumab and 8 received IMFINZI only. In the dose-expansion phase, an ORR of 5.0% (1/20 patients) was reported in the evaluable for response analysis set. No new safety signals were observed relative to the known safety profiles of IMFINZI and tremelimumab in adults. See section 4.2 for information on paediatric use.

5.2 Pharmacokinetic properties

The pharmacokinetics (PK) of durvalumab was assessed for IMFINZI as a single agent, in combination with chemotherapy, in combination with tremelimumab and platinum-based chemotherapy, in combination with tremelimumab and in combination with platinum-based chemotherapy followed by IMFINZI in combination with olaparib.

The PK of durvalumab was studied in 2903 patients with solid tumours with doses ranging from 0.1 to 20 mg/kg administered intravenously once every two, three or four weeks as monotherapy. PK exposure increased more than dose-proportionally (non-linear PK) at doses < 3 mg/kg, and dose proportionally (linear PK) at doses $\geq$ 3 mg/kg. Steady state was achieved at approximately 16 weeks. Based on population PK analysis that included 1878 patients who received durvalumab monotherapy in the dose range of $\geq$ 10 mg/kg every 2 weeks, the geometric mean steady state volume of distribution (V_{ss}) was 5.64 L. Durvalumab clearance (CL) decreased over time resulting in a geometric mean steady state clearance (CL_{ss}) of 8.16 ml/h at Day 365; the decrease in CL_{ss} was not considered clinically relevant. The terminal half-life ($t_{1/2}$), based on baseline CL, was approximately 18 days. There was no clinically meaningful difference between the PK of durvalumab as a single agent, in combination with chemotherapy, in combination with tremelimumab and platinum-based chemotherapy, in combination with tremelimumab and in combination with platinum-based chemotherapy followed by IMFINZI in combination with olaparib. The primary elimination pathways of durvalumab are protein catabolism via reticuloendothelial system or target mediated disposition.

Special populations

Age (19-96 years), body weight (31-149 kg), gender, positive anti-drug antibody (ADA) status, albumin levels, LDH levels, creatinine levels, soluble PD-L1, tumour type, race or ECOG status had no clinically significant effect on the PK of durvalumab.

Renal impairment

Mild (creatinine clearance (CrCL) 60 to 89 ml/min) and moderate renal impairment (creatinine clearance (CrCL) 30 to 59 ml/min) had no clinically significant effect on the PK of durvalumab. The effect of severe renal impairment (CrCL 15 to 29 ml/min) on the PK of durvalumab is unknown; however, as IgG monoclonal antibodies are not primarily cleared via renal pathways, a change in renal function is not expected to influence durvalumab exposure.

Hepatic impairment

Mild hepatic impairment (bilirubin $\leq$ ULN and AST > ULN or bilirubin > 1.0 to 1.5 x ULN and any AST) or moderate hepatic impairment (bilirubin > 1.5 to 3 x ULN and any AST) had no clinically significant effect on the PK of durvalumab. The effect of severe hepatic impairment (bilirubin > 3.0 x ULN and any AST) on the pharmacokinetics of durvalumab is unknown; however, as IgG monoclonal antibodies are not primarily cleared via hepatic pathways, a change in hepatic function is not expected to influence durvalumab exposure.

Paediatric population

The PK of durvalumab in combination with tremelimumab was evaluated in a study of 50 paediatric patients with an age range from 1 to 17 years in study D419EC00001. Patients received either durvalumab 20 mg/kg in combination with tremelimumab 1 mg/kg or durvalumab 30 mg/kg in combination with tremelimumab 1 mg/kg intravenously every 4 weeks for 4 cycles, followed by durvalumab as monotherapy every 4 weeks. Based on population PK analysis, durvalumab systemic exposure in paediatric patients ≥ 35 kg receiving durvalumab 20 mg/kg every 4 weeks was similar to exposure in adults receiving durvalumab 20 mg/kg every 4 weeks, whereas in paediatric patients (≥ 35 kg) receiving durvalumab 30mg/kg every 4 weeks, exposure was approximately 1.5-fold higher compared to exposure in adults receiving durvalumab 20 mg/kg every 4 weeks. In paediatric patients < 35 kg receiving durvalumab 30 mg/kg every 4 weeks, the systemic exposure was similar to exposure in adults receiving durvalumab 20 mg/kg every 4 weeks.

5.3 Preclinical safety data

Carcinogenicity and mutagenicity

The carcinogenic and genotoxic potential of durvalumab has not been evaluated.

Reproductive toxicology

As reported in the literature, the PD-1/PD-L1 pathway plays a central role in preserving pregnancy by maintaining maternal immune tolerance to the foetus, and in mouse allogeneic pregnancy models disruption of PD-L1 signalling was shown to result in an increase in foetal loss. In animal reproduction studies, administration of durvalumab to pregnant cynomolgus monkeys from the confirmation of pregnancy through delivery, at exposure levels approximately 18-times higher than those observed at the clinical dose of 10 mg/kg of durvalumab (based on AUC), was associated with placental transfer but not with maternal toxicity or effects on embryofoetal development, pregnancy outcome or postnatal development. Negligible levels of durvalumab was found in milk of cynomolgous monkey on Day 28 after birth.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Histidine
Histidine hydrochloride monohydrate
Trehalose dihydrate
Polysorbate 80 (E 433)
Water for injections

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

Unopened vial

3 years.

Diluted solution

Chemical and physical in-use stability has been demonstrated for up to 30 days at 2 °C to 8 °C and for up to 24 hours at room temperature (up to 25 °C) from the time of preparation.

From a microbiological point of view, the prepared solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the

user and would normally not be longer than 24 hours at 2 °C to 8 °C or 12 hours at room temperature (up to 25 °C), unless dilution has taken place in controlled and validated aseptic conditions.

6.4 Special precautions for storage

Store in a refrigerator (2 °C – 8 °C).

Do not freeze.

Store in the original package in order to protect from light.

For storage conditions after dilution of the medicinal product, see section 6.3.

6.5 Nature and contents of container

Two pack sizes of IMFINZI are available:

2.4 ml (a total of 120 mg durvalumab) of concentrate in a Type 1 glass vial with an elastomeric stopper and a grey flip-off aluminium seal. Pack size of 1 vial.

10 ml (a total of 500 mg durvalumab) of concentrate in a Type 1 glass vial with an elastomeric stopper and a white flip-off aluminium seal. Pack size of 1 vial.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

Preparation of solution

IMFINZI is supplied as a single-dose vial and does not contain any preservatives, aseptic technique must be observed.

- Visually inspect the medicinal product for particulate matter and discolouration. IMFINZI is clear to opalescent, colourless to slightly yellow solution. Discard the vial if the solution is cloudy, discoloured or visible particles are observed. Do not shake the vial.
- Withdraw the required volume from the vial(s) of IMFINZI and transfer into an intravenous (IV) bag containing sodium chloride 9 mg/ml (0.9%) solution for injection, or glucose 50 mg/ml (5%) solution for injection. Mix diluted solution by gentle inversion. The final concentration of the diluted solution should be between 1 mg/ml and 15 mg/ml. Do not freeze or shake the solution.
- Discard any unused portion left in the vial.

Administration

- Administer the infusion solution intravenously over 1 hour through an intravenous line containing a sterile, low-protein binding 0.2 or 0.22 micron in-line filter.
- Do not co-administer other medicinal products through the same infusion line.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

AstraZeneca AB
SE-151 85 Södertälje
Sweden

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/18/1322/002 120 mg vial
EU/1/18/1322/001 500 mg vial

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 21 September 2018
Date of latest renewal: 24 April 2023

10. DATE OF REVISION OF THE TEXT

12 March 2026

Detailed information on this medicinal product is available on the website of the European Medicines Agency <https://www.ema.europa.eu>.

ONC 26 0006